1 Characterization of direct and/or indirect genetic associations for multiple traits in 2 longitudinal studies of disease progression

- Myriam Brossard,^{*,1} Andrew D. Paterson,^{†,‡} Osvaldo Espin-Garcia,^{‡,**,§§} Radu V. Craiu,^{**} Shelley
 B. Bull^{*,‡,1}
- ⁵ ^{*}Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, M5T 3L9, Ontario, Canada;
- ⁶ [†]Program in Genetics and Genome Biology, Hospital for Sick Children Research Institute, M5G
- 7 1X8, Toronto, Ontario, Canada;
- 8 [‡]Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, M5T 3M7,
- 9 Toronto, Ontario, Canada;
- 10 [§]Department of Biostatistics, Princess Margaret Cancer Centre, M5G 2C1, Toronto, Ontario,
- 11 Canada;
- ^{**}Department of Statistical Sciences, University of Toronto, M5S 3G3, Toronto, Ontario, Canada;
- 13 ^{§§}Department of Epidemiology and Biostatistics, Western University, N6A 5C1, London, Ontario,
- 14 Canada.

15 Abstract

- 16 When quantitative longitudinal traits are risk factors for disease progression and subject to random
- 17 biological variation, joint model analysis of time-to-event and longitudinal traits can effectively
- 18 identify direct and/or indirect genetic association of single nucleotide polymorphisms (SNPs) with
- 19 time-to-event. We present a joint model that integrates: *i*) a multivariate linear mixed model 20 describing trajectories of multiple longitudinal traits as a function of time, SNP effects, and
- describing trajectories of multiple longitudinal traits as a function of time, SNP effects, and subject-specific random effects, and *ii*) a frailty Cox survival model that depends on SNPs,
- 22 longitudinal trajectory effects, and subject-specific frailty accounting for dependence among
- 23 multiple time-to-event traits. Motivated by complex genetic architecture of type 1 diabetes
- 24 complications (T1DC) observed in the Diabetes Control and Complications Trial (DCCT), we
- 25 implement a two-stage approach to inference with bootstrap joint covariance estimation and
- 26 develop a hypothesis testing procedure to classify direct and/or indirect SNP association with each
- time-to-event trait. By realistic simulation study, we show that joint modelling of two time-to T1DC (retinopathy, nephropathy) and two longitudinal risk factors (HbA1c, systolic blood
- 29 pressure) reduces estimation bias in genetic effects and improves classification accuracy of direct 30 and/or indirect SNP associations, compared to methods that ignore within-subject risk factor
- 31 variability and dependence among longitudinal and time-to-event traits. Through DCCT data 32 analysis, we demonstrate feasibility for candidate SNP modelling, and quantify effects of sample
- 33 size and Winner's curse bias on classification for two SNPs identified as having indirect
- 34 associations with time-to-T1DC traits. Overall, joint analysis of multiple longitudinal and multiple
- 35 time-to-event traits provides insight into complex trait architecture.

36 **Running title: Joint models for multiple-trait genetics.**

- 37 **Key words:** joint models; longitudinal study; direct and/or indirect genetic association; pleiotropy;
- 38 complex genetic architecture; multiple-trait analysis; random measurement error; quantitative trait
- 39 trajectory; mixed model; frailty model.
- 40 ¹**Corresponding authors:** Lunenfeld-Tanenbaum Research Institute, 60 Murray Street, Box #18,
- 41 M5T 3L9, Toronto, Ontario, Canada. E-mails: <u>bull@lunenfeld.ca</u>, <u>brossard@lunenfeld.ca</u>. Phone
- 42 number: +1 416-586-5052.

43

INTRODUCTION

44 Despite their known ability to improve inference in clinical and epidemiological studies, 45 particularly in the presence of informative censoring/dropout or when longitudinal traits are 46 measured with biological random variation (Hogan and Laird 1998; Ibrahim et al. 2010; Chen et 47 al. 2011), joint models for longitudinal and time-to-event (TTE) outcomes have received limited 48 attention in genetic association study design and analysis. Genome-wide association studies 49 (GWAS) of quantitative traits (QTs) often require follow-up analyses to identify whether SNP 50 associations detected with each of the QT(s), analyzed separately, also affect related disease 51 outcomes through direct and/or indirect effects induced by those QTs (Fig. 1). Such QTs can 52 include established intermediate risk factors for clinical outcomes, which may be measured with 53 high within-subject variability (e.g. random biological variation). By accounting for random 54 measurement error in intermediate QT risk factors and dependencies among traits, joint model 55 analysis can improve accuracy and efficiency of effect estimation, as well as detection and 56 interpretation of SNP associations.

57 The multiple-trait extensions we develop stem from a random-effects joint model that consists of 58 a sub-model for a single longitudinal trait linked to a sub-model for a single right-censored time-59 to-event trait (Wu et al. 2012; Asar et al. 2015). The longitudinal sub-model describes the QT as 60 an underlying smooth trajectory that depends on fixed effects of time and baseline covariates, as 61 well as subject-specific random effects. The joint model association structure is induced via the 62 functional dependence between the hazard of an event at time t and the longitudinal trait trajectory 63 (Hickey et al. 2016; Papageorgiou et al. 2019). Specification of this relationship can be based on 64 prior biological knowledge of the link between the longitudinal and time-to-event traits. As 65 previously elucidated, this class of joint models provides interpretations of direct and/or indirect

66 effects because the relationship between a baseline covariate, such as a SNP genotype, and each 67 of the longitudinal and time-to-event traits, as well as the relationship between the longitudinal 68 and time-to-event traits can be specified via model parameters corresponding to direct, indirect 69 and overall effects (Ibrahim et al. 2010). In this report, we demonstrate that extensions to jointly 70 model multiple longitudinal and multiple time-to-event traits can further improve inference by (i)71 borrowing information shared among correlated traits, and (ii) accounting for indirect genetic 72 pathways from multiple longitudinal QT risk factors, that if ignored, can confound an indirect 73 genetic association with a direct association.

74 Joint model extensions have been reviewed for multiple longitudinal traits (Hickey et al. 2016; 75 Papageorgiou et al. 2019) and for multiple time-to-event traits (Hickey et al. 2018a). Although a 76 few extensions have been developed for both multiple longitudinal and multiple time-to-event 77 traits, for example (Zhu et al. 2012; Tang et al. 2014; Tang and Tang 2014), these models are often 78 formulated for a specific study question, and thus can lack generalizability. In addition, such 79 extensions raise computational challenges for maximisation of the marginal likelihood that 80 integrates over the distribution of the multivariate random effects. Two-stage approaches for joint 81 model fitting are computationally efficient and allow more flexible model formulations (Self and 82 Pawitan 1992; Tsiatis et al. 1995; Bycott and Taylor 1998; Dafni and Tsiatis 1998). However, in 83 some circumstances, inference can be mis-calibrated when parameter estimates and predictions 84 from Stage 1 are obtained from the longitudinal model without consideration of the time-to-event 85 outcome, or when the uncertainty in Stage 1 estimates is ignored during Stage 2 estimation 86 (Wulfsohn and Tsiatis 1997), a problem known as propagation of errors.

87 Motivated by the complex genetic architecture of long-term type 1 diabetes complications (T1DC), 88 we develop a joint-model extension to evaluate genetic associations with multiple longitudinal QT 89 risk factors and multiple TTE traits. Risk of development of T1DC, including diabetic retinopathy 90 (DR) and diabetic nephropathy (DN), is hypothesized to result from multiple genetic factors with 91 potential direct and/or indirect effects induced via multiple shared and/or specific QT risk factors 92 (Paterson and Bull 2012). Besides potential genetic factors, hyperglycemia (measured by 93 Hemoglobin A1c, hereafter abbreviated as HbA1c) represents a major risk factor for T1DC; 94 intensive insulin therapy to control the HbA1c level to a normal range prevents and delays 95 progression of long-term T1DC, as demonstrated by the Diabetes Control and Complications Trial 96 (DCCT, (The Diabetes Control and Complications Trial Research Group 1993)). The first GWAS 97 to analyze the DCCT study phenotypes identified two SNPs associated with within-patient mean 98 HbA1c at genome-wide significance in the Conventional treatment arm, namely rs10810632 (in 99 BNC2, 9p22.2) and rs1358030 (near SORCS1, 10q25.1), and reported weaker SNP associations 100 with the secondary outcomes time-to-DR and/or time-to-DN (Paterson et al. 2010). Genetic 101 association studies also reported variants with potential pleiotropic effects on DR and DN 102 (Hosseini et al. 2015). Other measured longitudinal QTs, also influenced by genetic factors, are 103 postulated to have associations with T1DC, for example, association of systolic blood pressure 104 (SBP) with DN.

Our objective is to develop an integrated approach to investigate the complex genetic architecture of disease complications, and associated risk factors, as in the motivating study of type 1 diabetes complications. The approach we develop entails multiple longitudinal risk factors and multiple time-to-event outcomes, as well as multiple SNP associations with multiple traits. In addition to genetic variants associated with risk factors, the model needs to handle multiple longitudinal quantitative risk factors that can be related to more than one complication, and genetic variants that can affect risk of more than one complication directly and/or indirectly through intermediate risk factor(s); accounting for known intermediate longitudinal QTs is essential to correctly distinguish between direct and indirect genetic effects on each T1DC trait. To this end, we formulate a general model extension to multiple longitudinal QTs and multiple TTE traits, which proposes correlated random effects and a frailty term to address dependency among QTs and among TTE traits.

117 Based on the DCCT study, we hypothesize a multi-trait model for T1DC genetic architecture, and 118 develop methods to investigate it. Because the goal of intensive therapy in DCCT was to reduce 119 HbA1c into the non-diabetic range, which produced treatment differences in HbA1c values, we 120 base our joint model evaluation and application on N=667 unrelated individuals of European 121 ancestry from the Conventional treatment group. Longitudinal measurements for HbA1c and SBP 122 were recorded irrespective of the occurrence of any complication event(s) at up to 39 quarterly 123 visits (See File S1 for a description of the DCCT dataset we analysed). HbA1c and SBP are 124 established risk factors for T1DC, and genetic association with either risk factor can induce an 125 indirect genetic association with T1DC. The latter can be mistaken as a direct genetic association 126 when the intermediate longitudinal risk factor(s) is ignored. Distinguishing between direct and/or 127 indirect genetic effects can help to reveal genetic pathways in the aetiology of T1DC with 128 implications for the direction of on-going investigations, and development of new intervention 129 strategies. Nevertheless, accurate classification of direct and/or indirect SNP associations is 130 challenged by within-patient variability in intermediate QT(s), and unmeasured shared risk factors 131 among longitudinal and time-to-event traits.

132 The *primary* contribution of our work is a general formulation of a joint model for multiple 133 longitudinal QT risk factors and multiple time-to-event traits in genetic association studies. We 134 develop inference methods for statistical genetic analysis using a two-stage approach to joint 135 model parameter estimation and hypothesis testing, including a procedure to classify SNP 136 associations with each time-to-event trait as direct and/or indirect. A second contribution of this 137 paper is the development of a data-informed simulation algorithm, under the postulated multi-trait 138 model for T1DC genetic architecture, to generate multiple causal SNPs with various direct effects 139 on simulated TTE traits and/or indirect effects via observed (measured) longitudinal QTs in DCCT 140 and unobserved (simulated) longitudinal QTs. This algorithm provides a general approach to 141 estimate power of the joint modeling approach (in comparison to alternative methods) given study 142 sample size and various direct/indirect genetic associations via observed or unobserved 143 longitudinal QT(s) risk factors for time to disease complications. Our numerical investigations 144 show that the proposed method reduces estimation bias and improves accuracy of classification of 145 direct and/or indirect SNP associations in comparison with separate joint models for each pair of 146 longitudinal QT and time-to-event trait, and approaches that ignore measurement error in 147 longitudinal QT(s). Lastly, we show computational feasibility and interpretation in an extended 148 joint model application to DCCT genetic association analyses of candidate SNPs. Using the 149 proposed procedure, we classify rs10810632 and rs1358030 as having indirect association with 150 two T1DC traits via the HbA1c longitudinal risk factor, and obtain similar conclusions using 151 alternative time-dependent association structures that account for cumulative and time-weighted 152 effects of HbA1c on T1DC traits (Lind et al. 1995; Lind et al. 2010). Example programs written 153 in R for data simulation and for application of the proposed joint model are available on GitHub.

154

MATERIALS AND METHODS

155 Model Formulation

156 We assume that a set of M SNPs have been genotyped, together with observation of K ($1 \le k \le K$) unordered and non-competing time-to-event traits, such as multiple disease complications, and L 157 158 $(1 \le l \le L)$ longitudinal QTs (*i.e.* intermediate risk factors) measured in N unrelated individuals indexed by i $(1 \le i \le N)$. To characterize the genetic architecture of multiple longitudinal risk 159 160 factors and multiple time-to-events, we formulate a shared-random-effects joint model that 161 connects longitudinal and time-to-event sub-models through specified time-dependent association 162 structures. For ease of presentation, we simplify the model notation by assuming no adjusting 163 covariates but note that trait-specific and/or shared covariates, such as confounding factors or 164 ancestry-related principal components can be easily incorporated. We first introduce the joint 165 model for one longitudinal trait (L = 1) and one time-to-event trait (K = 1). Then, in the 166 subsequent subsection, we present the extension for an arbitrary number of longitudinal and time-167 to-event traits.

Joint model for *one* longitudinal and *one* time-to-event trait – For each individual *i*, we define $y_i = (y_{i,1}, ..., y_{i,j}, ..., y_{i,j})$, as the vector of QT measures collected over the *J* visit times $t_i =$ $(t_{i,1}, ..., t_{i,j}, ..., t_{i,j})^T$ with $1 \le j \le J$ and $t_{i,1} \le \cdots \le t_{i,j} \le \cdots \le t_{i,J}$. We denote (T_i, δ_i) as the vector of right-censored event time T_i and event indicator δ_i for the time-to-event trait, and assume $T_i = \min(T_i^*, C_i)$, where T_i^* is the latent (uncensored) event time and C_i is the censoring time (e.g., administrative censoring). We define $\delta_i = I(T_i^* \le C_i)$, with $\delta_i = 1$ if the event occurs during the observation period, and $\delta_i = 0$ otherwise.

175 *Longitudinal sub-model.* This is specified by a mixed-effects model for the longitudinal QT, based 176 on the (Laird and Ware 1982) linear mixed model. The model builds on the assumption that for 177 every individual in the sample there exists an underlying smooth trajectory of the longitudinal QT 178 that describes the subject-specific evolution dependent on time, SNP effect, and individual-level 179 random effects b_i . To simplify the presentation, we assume a linear QT trajectory (Equation 1), 180 but the longitudinal sub-model can be adapted for nonlinear trajectories using, for example, higher 181 order polynomials or splines (Rizopoulos 2012):

182
$$y_i^*(t) = \beta_0 + b_{i,0} + (\beta_1 + b_{i,1})t + \beta_g g_i$$
 (Equation 1, smooth linear trajectory)

g_i, is the genotype of the individual *i* for the SNP being tested, coded as the number of
 copies of the minor allele,

186 • $\boldsymbol{\beta} = (\beta_0, \beta_1, \beta_g)^T$ is the vector of fixed intercept and slope time effects and fixed genetic 187 effect on the longitudinal QT,

188 • $\boldsymbol{b}_{i} = (b_{i,0}, b_{i,1})^{T}$ are the subject-specific random intercept and slope time effects assuming

189 $\boldsymbol{b}_i \sim N_2(0, \boldsymbol{D})$ and \boldsymbol{D} is the variance-covariance matrix.

190 This trajectory cannot be observed directly, rather we observe longitudinal measurements y_i 191 collected at discrete time points t_i ; measurements are subject to independent and identically 192 distributed noise contamination variables $\varepsilon_i \sim N_J(0, \Sigma)$, where $\varepsilon_i = (\varepsilon_{i,1}, ..., \varepsilon_{i,j}, ..., \varepsilon_{i,J})^T$, $\Sigma =$ 193 $\sigma^2 I_I$, with σ^2 , the residual variance of the QT:

194
$$\mathbf{y}_i = y_i^*(\mathbf{t}_i) + \boldsymbol{\varepsilon}_i$$
 (Equation 2, vector of observed trait values)

195 We assume that \boldsymbol{b}_i and $\boldsymbol{\varepsilon}_i$ are independent (Laird and Ware 1982).

196 Equation 2 implies that y_i in \Re^J follows a multivariate normal distribution with:

197
$$E[\mathbf{y}_i] = \mathbf{X}_i \boldsymbol{\beta}$$
 and $Var[\mathbf{y}_i] = \mathbf{Z}_i \boldsymbol{D} \mathbf{Z}_i^T + \boldsymbol{\Sigma}$,

where $X_i = (\mathbf{1}_I, \mathbf{t}_i, g_i \mathbf{1}_I)$ denotes the (*J*-by-3) design matrix for the fixed intercept, slope, and 198 SNP effects, and $\mathbf{Z}_i = (\mathbf{1}_J, \mathbf{t}_i)$ is the (*J*-by-2) design matrix for the random intercept and slope 199 effects, with $\mathbf{1}_I = (1, ..., 1, ..., 1)^T$. To increase robustness to misspecification of the variance-200 201 covariance matrix D, we adopt an unstructured form for the random-effects variance, defined as $\boldsymbol{D} = \begin{pmatrix} \operatorname{Var}(b_{i,0}) & \operatorname{Cov}(b_{i,0}, b_{i,1}) \\ \operatorname{Cov}(b_{i,0}, b_{i,1}) & \operatorname{Var}(b_{i,1}) \end{pmatrix}, \text{ with the added benefit of not requiring additional}$ 202 constraints on the serial dependence between the repeated measurements for each individual. This 203 204 choice implies that the covariance function between any pair of QT observations for individual *i* collected at two distinct visit times $t_{i,j} \neq t_{i,s}$ $(1 \le j \le J \text{ and } 1 \le s \le J, \text{ with } j \ne s)$ is given by 205 $Cov(y_{i,j}, y_{i,s}) = t_{i,j}t_{i,s}Var(b_{i,1}) + (t_{i,j} + t_{i,s})Cov(b_{i,0}, b_{i,1}) + Var(b_{i,0}) + \sigma^2$, with variance 206 function $Var(y_{i,j}) = t_{i,j}^2 Var(b_{i,1}) + 2t_{i,j} Cov(b_{i,0}, b_{i,1}) + Var(b_{i,0}) + \sigma^2$, which is quadratic 207 over time with positive curvature at $Var(b_{i,1})$. 208

Time-to-event sub-model. This is specified by a proportional hazards model (PH model), in which the hazard function of the time-to-event trait is defined as the instantaneous event rate in a small interval around T_i^* given that the event has not occurred before time *t*, genetic effect and a function of the history of the true unobserved longitudinal process up to time *t* that is associated with risk

of the event, $W_i(t) = f(Y_i^*(t))$, with $Y_i^*(t) = \{y_i^*(s), 0 \le s \le t\}$. We specify that the hazard function (Equation 3) depends on the SNP effect adjusted for association of the longitudinal QT risk factor with the time-to-event trait.

216 Now,
$$\lambda_i(t) = \lim_{dt \to 0} \Pr\{t \le T_i^* < t + dt \mid T_i^* \ge t, W_i(t) = f(Y_i^*(t)), g_i\}/dt$$

217 and we assume
$$\lambda_i(t) = \lambda_0(t) \times exp\{\alpha w_i(t) + \gamma_q g_i\}$$
 (Equation 3)

218 Where:

• $\lambda_0(t)$ is a (parametric or non-parametric) baseline hazard function;

• $w_i(t) = f(y_i^*(t))$ specifies the function of the longitudinal QT trajectory accounting for trajectory values at time *t* that is associated with risk of the event. In the case of a *contemporaneous* parametrization, the hazard of an event at a time *t* depends on the longitudinal trajectory value at the same time t (*i.e.* $w_i(t) = y_i^*(t)$). Other functional forms of the QT trajectory can weight earlier QT values according to prior knowledge of the relationship of the QT with the time-to-event trait (Hickey et al. 2016; Mauff et al. 2017; Papageorgiou et al. 2019);

- α is the effect of the longitudinal QT risk factor on the time-to-event trait;
- γ_g denotes the genetic effect on the time-to-event trait accounting for association of the longitudinal QT risk factor with the time-to-event trait.

Interpretation. As depicted in Fig. 1, the joint model parameters characterize relationships among
a SNP, an intermediate QT, and a time-to-event trait and decompose possible effects of a SNP on

| 232 | a time-to-event trait into: an indirect effect induced via the SNP effect on the longitudinal QT; and |
|------|---|
| 233 | a direct SNP effect independent of the QT (Ibrahim et al. 2010; Hickey et al. 2018b). |
| | |
| 234 | Based on the SNP effects, β_g and γ_g , and assuming $\alpha \neq 0$, a SNP association with a time-to-event |
| 235 | trait can be one of three types: |
| 236 | • indirect SNP association: the SNP has a non-null effect on the longitudinal QT ($\beta_g \neq 0$), |
| 237 | but no effect on the time-to-event trait ($\gamma_g = 0$); the overall SNP effect θ depends on the |
| 238 | indirect effect ($\theta = \mu_g$, with $\mu_g = \alpha \beta_g$). |
| 239 | • direct SNP association: the SNP has a non-null effect on the time-to-event trait ($\gamma_g \neq 0$), |
| 240 | but no effect on the longitudinal QT ($\beta_g = 0$); the overall SNP effect depends only on the |
| 241 | direct effect ($\theta = \gamma_g$). |
| 242 | • both direct and indirect SNP associations: the SNP has non-null effects on the longitudinal |
| 243 | risk factor ($\beta_g \neq 0$) and on the time-to-event trait ($\gamma_g \neq 0$). In this case, the overall SNP |
| 244 | effect θ aggregates the indirect and direct SNP effects ($\theta = \mu_g + \gamma_g$, with $\mu_g = \alpha \beta_g$). |
| 0.45 | |

In later subsections, we detail statistical implementation for estimation of the α , β_g and γ_g parameters and associated hypothesis testing in the joint model, which underlie the procedure we then propose to classify the SNP association as indirect, direct, or both direct and indirect.

When an associated longitudinal risk factor is omitted from the time-to-event model, the estimated SNP effect on the time-to-event trait captures the overall SNP effect ($\theta = \mu_g + \gamma_g$). This can occur in GWAS when the time-to-event analysis ignores an intermediate risk factor or when the time-to-event trait is associated with more than one intermediate risk factor. This observation also illustrates one of the limitations of the joint model for *one* longitudinal with *one* time-to-event trait,

with the consequence that an indirect SNP association can be mistaken as a direct association whenother longitudinal risk factors are omitted in the joint model.

255 Generalization of the joint model to multiple longitudinal and multiple time-to-event traits -256 To characterize the genetic architecture of a system of multiple longitudinal risk factors and 257 multiple time-to-events, we propose an extension of the joint model to L longitudinal and K timeto-event traits (L>1, K>1), as shown in Fig. 2 and detailed as follows. We define $y_{i,l}$ = 258 $(y_{i,l,1}, ..., y_{i,l,j}, ..., y_{i,l,J})$ as the observed longitudinal measures for each l^{th} QT, $1 \le l \le L$, collected 259 over the J visit times t_i . We define $(T_{i,k}, \delta_{i,k})$ as the vector of observed right-censored event time 260 $T_{i,k}$ and event indicator $\delta_{i,k}$ for each k^{th} time-to-event trait for individual *i*, with $\delta_{i,k} = I(T_{i,k}^* \leq 1)$ 261 C_i). We assume the same censoring time C_i across all K outcomes, but the model can be extended 262 to situations where C_i varies for each time-to-event trait. Again, for ease of presentation, we 263 264 simplify the model notation with no adjusting covariates and assume linear trajectories for all L 265 longitudinal traits and contemporaneous effects of L longitudinal traits on the K time-to-event 266 traits. The model can be extended to account for non-linear trajectories, cumulative longitudinal 267 effects, and trait-specific and/or shared covariates such as confounding factors or ancestry-related 268 principal components.

269

270 *Multivariate longitudinal sub-model.* In the extension of the longitudinal sub-model to L271 longitudinal traits, we index subscripts in Equations 1 and 2 for each l^{th} longitudinal trait 272 (Equations 4 and 5 in Fig 2). The vector of observed trait values becomes:

273
$$\mathbf{y}_{i,l} = \mathbf{X}_{i,l} \boldsymbol{\beta}_l + \mathbf{Z}_i \boldsymbol{b}_{i,l} + \boldsymbol{\varepsilon}_{i,l}$$
 (observed repeated measures for the l^{th} QT)

Where:

•
$$X_{i,l} = (\mathbf{1}_J, t_i, g_i \mathbf{1}_J)$$
 and $Z_{i,l} = (\mathbf{1}_J, t_i)$ are the design matrices for fixed and random effects,

•
$$\boldsymbol{\beta}_{l} = (\beta_{0,l}, \beta_{1,l}, \beta_{g,l})^{T}$$
 and $\boldsymbol{b}_{i,l} = (b_{i,0,l}, b_{i,1,l})^{T}$ denote the QT-specific fixed and random

effects,

•
$$\boldsymbol{\varepsilon}_{i,l} = (\boldsymbol{\varepsilon}_{i,1,l}, \dots, \boldsymbol{\varepsilon}_{i,j,l}, \dots, \boldsymbol{\varepsilon}_{i,j,l})^T$$
 is the vector of residual error terms, with $\boldsymbol{\varepsilon}_{i,l} \sim N_J(\mathbf{0}, \boldsymbol{\Sigma}_l)$,

280 where $\Sigma_l = \sigma_l^2 I_J$ with σ_l^2 , the residual variance for the *l*th QT; we assume the $\varepsilon_{i,l}$ are 281 independent for all *L* traits.

282 To account for dependence among the *L* longitudinal QTs, we assume the overall random effects

283 vector for all *L* QTs,
$$\boldsymbol{b}_i = (\boldsymbol{b}_{i,1}, \dots, \boldsymbol{b}_{i,L})^T \sim N_{2L}(\boldsymbol{0}, \boldsymbol{D})$$
, where $\boldsymbol{D} = \begin{pmatrix} \boldsymbol{D}_{1,1} & \cdots & \boldsymbol{D}_{1,L} \\ \vdots & \boldsymbol{D}_{L,l} & \vdots \\ \boldsymbol{D}_{L,1} & \cdots & \boldsymbol{D}_{L,L} \end{pmatrix}$ is

the variance-covariance matrix for all L QTs, accounting for serial dependencies within each l^{th}

285 QT, i.e. $\boldsymbol{D}_{l,l} = \begin{pmatrix} \operatorname{Var}(b_{i,0,l}) & \operatorname{Cov}(b_{i,0,l}, b_{i,1,l}) \\ \operatorname{Cov}(b_{i,0,l}, b_{i,1,l}) & \operatorname{Var}(b_{i,1,l}) \end{pmatrix}$, and accounting for cross-dependencies

286 between each pair l, m of QTs with $l \neq m$, that is $\boldsymbol{D}_{l,m} = \begin{pmatrix} \operatorname{Cov}(b_{i,0,l}, b_{i,0,m}) & \operatorname{Cov}(b_{i,0,l}, b_{i,1,m}) \\ \operatorname{Cov}(b_{i,1,l}, b_{i,0,m}) & \operatorname{Cov}(b_{i,1,l}, b_{i,1,m}) \end{pmatrix}$.

This formulation implies that the vector of stacked repeated measures for all *L* longitudinal QTs for individual *i*, $\mathbf{y}_i = (\mathbf{y}_{i,1}, ..., \mathbf{y}_{i,L})^T$ in $\Re^{J \times L}$ follows a multivariate normal distribution with mean $E[\mathbf{y}_i] = \mathbf{X}_i \boldsymbol{\beta}$ and variance $Var[\mathbf{y}_i] = \mathbf{Z}_i D \mathbf{Z}_i^T + \boldsymbol{\Sigma}$, where:

• $X_i = diag(X_{i,1}, ..., X_{i,l}, ..., X_{i,L})$ and $Z_i = diag(Z_{i,1}, ..., Z_{i,l}, ..., Z_{i,L})$ are the overall (*JL*-by-3*L*) and (*JL*-by-2*L*) design block diagonal matrices for the fixed and random effects respectively;

•
$$\boldsymbol{\beta} = (\boldsymbol{\beta}_1, ..., \boldsymbol{\beta}_L, ..., \boldsymbol{\beta}_L)^T$$
 is the 3*L*-length stacked vector of fixed effects,

• **D** is the (2L-by-2L) covariance matrix for random effects
$$\boldsymbol{b}_i = (\boldsymbol{b}_{i,1}, \dots, \boldsymbol{b}_{i,l}, \dots, \boldsymbol{b}_{i,L})^T$$
,

• $\Sigma = diag(\Sigma_1, ..., \Sigma_l, ..., \Sigma_L)^T$ is the (*JL*-by-*JL*) block diagonal matrix of residual variances.

Assuming, for each l^{th} QT, an unstructured variance-covariance matrix $D_{l,l}$, the variance at each 297 visit time $t_{i,j}$ is $Var(y_{i,j,l})$ and the covariance function $Cov(y_{i,j,l}, y_{i,s,l})$ between two visit times 298 $t_{i,j} \neq t_{i,s}$ are analogous to those defined above for the joint model with a single longitudinal and 299 single time-to-event trait. The multivariate mixed model accounts for dependencies between each 300 QT pair $l \neq m$ via random-effect covariance functions in the $D_{l,m}$ matrices where the covariance 301 between observations of two QTs $(l, m; l \neq m)$ measured at the same visit time $t_{i,j}$ is 302 $Cov(y_{i,j,l}, y_{i,j,m}) = t_{i,j}^2 Cov(b_{i,1,l}, b_{i,1,m}) + t_{i,j} \left(Cov(b_{i,0,l}, b_{i,1,m}) + Cov(b_{i,0,m}, b_{i,1,l}) \right) +$ 303 $Cov(b_{i,0,l}, b_{i,0,m})$ which is quadratic over time, and the covariance function between two 304 longitudinal QTs $(l \neq m)$ measured at different visit times $t_{i,j} \neq t_{i,s}$ is $Cov(y_{i,j,l}, y_{i,s,m}) =$ 305

306 $t_{i,j}t_{i,s}\text{Cov}(b_{i,1,l}, b_{i,1,m}) + t_{i,j}\text{Cov}(b_{i,1,l}, b_{i,0,m}) + t_{i,s}\text{Cov}(b_{i,0,l}, b_{i,1,m}) + \text{Cov}(b_{i,0,l}, b_{i,0,m})$. Thus, 307 joint analysis of correlated longitudinal QTs is expected to improve power over separate analysis 308 of each QT by borrowing information through implied dependency structures among the random 309 effects.

310 *Multivariate time-to-event sub-model.* Finally, we extend Equation 3 to a multivariate PH frailty 311 time-to-event sub-model, with a subject-specific random effect (frailty term, u_i) introduced to 312 capture potential unexplained dependencies (e.g. due to unmeasured baseline shared factors) 313 among the time-to-event traits. In Equation 6 (Fig 2), $\lambda_{0,k}(t)$ and $\gamma_{g,k}$, correspond to the baseline 314 hazard function, and SNP effect on the k^{th} time-to-event trait ($1 \le k \le K$), accounting for association

of each l^{th} QT with the time-to-event trait k ($\alpha_{l,k}$, $1 \le l \le L$). We assume that the subjectspecific frailty term follows a gamma distribution, that is $u_i \sim \Gamma(a, b)$ with a, b > 0, and represents dependencies among the *K* traits. Equation 6 (Fig 2) can be expressed as:

318
$$\lambda_{i,k}(t) = \lambda_{0,k}(t) \times exp\{\alpha_k w_{i,k}(t) + \gamma_{g,k} g_i + u_i\},$$

319 where $\boldsymbol{\alpha}_{k} = (\alpha_{1,k}, ..., \alpha_{l,k}, ..., \alpha_{L,k})^{T}$ is the vector of all *L* QT effects on the *k*th time-to-event trait, 320 and $\boldsymbol{w}_{i,k}(t) = \left(w_{i,1,k}(t), ..., w_{i,l,k}(t), ..., w_{i,L,k}(t)\right)$ specifies the corresponding association 321 profile of each QT with the *k*th time-to-event trait. We note $w_{i,l,k}(t) = f_{l,k}\left(y_{i,l}^{*}(t)\right)$, where 322 $y_{i,l}^{*}(t)$, denotes the *l*th QT trajectory ($1 \le l \le L$) at time *t*, which depends on the fixed and random 323 effects $\boldsymbol{\beta}_{l}$ and $\boldsymbol{b}_{i,l}$.

324 Comparisons with joint model of one longitudinal and one time-to-event trait. In the proposed 325 joint model extension for multiple longitudinal and multiple time-to-event traits, the direct, indirect 326 and overall SNP effects defined above for the joint model with one longitudinal and one time-to-327 event trait are interpreted similarly. However, there are important practical differences between 328 the latter model for a pair of traits and the proposed multi-trait. First, because the joint model 329 extension can account for multiple intermediate longitudinal QT risk factors associated with one 330 (or multiple) time-to-event trait(s), it improves-inference for SNP association and accuracy of SNP 331 classification, particularly when a time-to-event trait depends on more than one longitudinal risk 332 factor as illustrated in our numerical experiments. Second, in the multivariate longitudinal sub-333 model, the variance-covariance matrix D for the random effects specifies non-null covariance terms in $D_{l,m}$ for each pair of longitudinal QT l, m $(1 \le l \le L \text{ and } 1 \le m \le L, l \ne m)$. In 334 contrast, under the assumption of null covariance terms in $D_{l,m}$ for all QT pairs inherent in separate 335 336 analyses of each QT, the multivariate sub-model reduces to independent sub-models for each

337 longitudinal QT. When longitudinal QTs are correlated, assuming null covariances can fail to make 338 use of information borrowed through the random effects and reduce efficiency of the parameter 339 estimates in the longitudinal trajectories (Shah et al. 1997; Jensen and Ritz 2018). This, in turn, 340 can affect estimation in the time-to-event model. *Third*, without a frailty term u_i , the time-to-event 341 sub-model (Equations 6 and 7) reduces to separate time-to-event sub-models for each time-to-342 event trait. Thus, through use of a shared frailty term, the extended joint model accounts for 343 residual dependency between the K time-to-event traits, not explained by the covariates shared by 344 the time-to-event sub-models. Overall, the proposed joint model for multiple longitudinal and 345 multiple time-to-event traits can improve inference by accounting for intermediate longitudinal 346 QT(s) and their dependencies, as well as dependencies among the time-to-event traits, and thereby 347 improve classification accuracy of direct and/or indirect SNP associations.

348 Implementation

349 *Effect estimation and test statistic construction* – To address computational obstacles involved in 350 the maximization of the joint likelihood and allow more flexible inference, we estimate the 351 parameters using a two-stage approach (see details in the Appendix). We work within the 352 framework originally defined by (Tsiatis et al. 1995; Wulfsohn and Tsiatis 1997; Dafni and Tsiatis 353 1998; Tsiatis and Davidian 2001) and in the spirit of subsequent authors (Ye et al. 2008; Yuen et 354 al. 2018; Arisido et al. 2019); (Tsiatis and Davidian 2001; Tsiatis and Davidian 2004) specify 355 conditions that guarantee the two-stage estimators are consistent and asymptotically normal. 356 Specifically, in Stage 1 we fit a multivariate mixed model (Equation 5) using the *mvlme()* function 357 from the R package JoineRML [(Hickey et al. 2018c), version 0.4.2] to estimate the parameters of 358 the longitudinal trajectories of the risk factors, and obtain fitted values of the smoothed trajectories.

In Stage 2, we fit a Cox PH frailty time-to-event model (Equations 6 or 7) adjusting for functions of the smoothed trajectories as time-dependent covariates using the coxph() function from the R package survival [(Therneau and Grambsch 2000; Therneau 2020), versions 3.2.7 and 3.2.13]. We assume a Gamma distribution for the frailty term (u_i) and a separate non-parametric baseline hazard function for each time-to-event trait using the strata argument in coxph().

To account for propagation of errors, due to uncertainty in Stage 1 estimates that is not accounted 364 365 for during Stage 2 parameter estimation (Wulfsohn and Tsiatis 1997), and to empirically estimate the joint covariance matrix of SNP-QT trajectory $(\beta_{g,l})$ and SNP-TTE effects $(\gamma_{g,k})$, we apply a 366 367 nonparametric bootstrap. The bootstrap also provides reliable standard error estimates in the joint 368 time-to-event sub-model needed when using an unspecified baseline hazard (Hsieh et al. 2006; 369 Lawrence Gould et al. 2015; Furgal et al. 2019). For each bootstrap sample b ($1 \le b \le B$, B is the 370 total number of bootstrap repetitions), we generate a new dataset by randomly sampling N371 individuals with replacement and refitting the joint model on each new dataset b. We compute the 372 empirical joint covariance matrix for all $\beta_{g,l}$, $\gamma_{g,k}$ and $\alpha_{l,k}$ parameter estimates using the B 373 bootstrap parameter vector estimates. Wald statistics for each $\beta_{g,l}$ are computed as S_{β_g} = $\widehat{\beta_{g,l}}/se_{\beta_{g,l}}$ using the empirical bootstrap standard errors $se_{\beta_{g,l}}$ (to test H0: $\beta_{g,l} = 0$ vs H1: $\beta_{g,l} \neq 0$ 374 0), and similarly for each $\gamma_{g,k}$ as $S_{\gamma_g} = \widehat{\gamma_{g,k}} / se_{\gamma_{g,k}}$ (to test H0: $\gamma_{g,k} = 0$ vs H1: $\gamma_{g,k} \neq 0$). 375

In contrast to the two-stage joint model, a conventional one-stage analysis to assess whether a SNP has an association with the time-to-event trait, independent from the QT-TTE association, relies on regression adjustment using observed longitudinal QT values as time-dependent covariates in a Cox-PH model (Paterson et al. 2010; Deng and Pan 2017). This approach, based only on the

380 time-to-event model, does not provide information about SNP-QT association ($\beta_{g,l}$) and interprets the SNP as having a direct association with the time-to-event if the test of SNP-TTE effect $(\gamma_{g,k})$ is 381 declared significant, given the observed QT. Inference for $\alpha_{l,k}$ under this approach can be biased 382 383 or inefficient when the QT is measured with random error or high within-subject variability 384 (Faucett and Thomas 1996; Wulfsohn and Tsiatis 1997; Xu and Zeger 2001; Song et al. 2002; Brown and Ibrahim 2003), and inference for $\gamma_{g,k}$ may also be affected. Although estimates of the 385 SNP-QT effect $(\beta_{g,l})$ obtained from mixed model QT analysis, fitted separately, may be used to 386 387 distinguish between direct alone versus both direct and indirect SNP association, unlike the joint 388 model, this two-step conditional approach ignores measurement error in the observed QT values.

389 Procedure to classify direct and/or indirect SNP associations - In Table 1, we present a 390 practical procedure to classify a SNP as having direct and/or indirect association with a time-to-391 event trait k, that accounts for the SNP association with a longitudinal risk factor l. This procedure requires two significance thresholds, $P_{\beta_g}^*$ and $P_{\gamma_g}^*$ for hypothesis tests of each of $\beta_{g,l}$ and $\gamma_{g,k}$ 392 393 respectively, to be specified prior to the analysis and adjusted for the number of SNPs tested. Depending on the research question, we can choose different values for P_{β}^* and P_{γ}^* , or the same 394 value $(P^* = P^*_{\beta_g} = P^*_{\gamma_g})$. The latter is applicable, for instance, to systematically classify direct 395 396 and/or indirect association for a set of M SNPs, and the former to assess which SNPs, among those 397 reported to be associated with the longitudinal risk factor, have a direct effect on a time-to-event 398 trait. To our knowledge, no comparable procedure to classify direct and/or indirect SNP 399 association, based on SNP effect estimates from joint models, has been proposed for studies with 400 longitudinal risk factors and time-to-event traits. A key feature of the proposed joint model 401 extension to multiple longitudinal and multiple time-to-event traits is inference for SNP effects on

402 each of the traits in a single integrated statistical model, while accounting for within-subject QT
403 variability and dependencies among the traits. The focus of the simulation study and DCCT data
404 application, which follow, is to evaluate the SNP classification procedure applied in extended joint
405 model analysis.

406 Simulation study

407 **Design of the DCCT-data-based simulation study** – To assess parameter estimation accuracy, 408 hypothesis testing for tests of each genetic effects under the proposed joint model, and evaluate 409 accuracy of the procedure we propose to classify SNPs as directly and/or indirectly associated with 410 a time-to-event trait, we generate R=1000 replicated datasets simulated under a *complex genetic* 411 architecture informed by the DCCT Genetics Study data (Fig. 3). The latter involves: N=667 412 subjects from the Conventional treatment group, M=5 simulated causal SNPs with direct effects 413 on K=2 simulated time-to-T1DC (with ~54% DR events and ~25% DN events on average) and/or 414 indirect effects via L=3 longitudinal QTs: two as measured in DCCT (HbA1c, SBP) and another 415 simulated OT (U) that is unmeasured and designed to induce shared dependency among the T1DC 416 traits. We assume effects of sex on SBP, and effects of T1D duration (at baseline) on both T1DC 417 traits, as estimated in the original DCCT data, and specify contemporaneous association structures 418 for the association of HbA1c and SBP on T1DC traits. We specify SNP effects and minor allele 419 frequencies (MAFs) of genetic associations, as well as other parameter values according to the 420 DCCT Genetics Study and the T1DC literature (Fig. 3). For SBP and DN, we inflate the typical 421 SNP effect sizes observed in the literature to achieve power sufficient to detect SNP associations 422 given the available DCCT sample size. Under the *global null genetic* scenario in which none of 423 the SNPs is associated with any traits, we also simulate M SNPs with the same MAFs as for the 424 causal SNPs, independently of the traits.

425 **Algorithm for realistic data generation under a complex genetic architecture** – To generate a 426 data structure that combines observed and simulated traits, we formulate a genotype-phenotype 427 multi-trait model including: (i) L=3 linear mixed models linking each SNP with an indirect effect 428 to a longitudinal risk factor, and (ii) K=2 non-independent parametric time-to-event models 429 depending on fitted longitudinal QT trajectories and SNPs with direct effects. For each DCCT 430 individual *i* with observed longitudinal measures for HbA1c and SBP, and observed baseline 431 covariates (T1D duration, sex), we simulate: genotypes at M causal SNPs with MAF vector p, longitudinal trait values U_i , and time-to-event traits ($(T_{i,k}, \delta_{i,k})$, k=1,2 for DR and DN), using the 432 433 algorithm illustrated in Fig. 4 and detailed in File S2 (sections 1-5). All SNP genotypes are 434 generated under Hardy-Weinberg and linkage equilibrium assumptions. SNPs with indirect effects 435 through longitudinal QTs associated with DR and/or DN are generated from the observed (SNP1, 436 SNP5) or simulated (SNP3) OTs, while SNPs with direct effects (SNP2, SNP4) are generated 437 independently of the longitudinal QTs and are included in the hazard function used to generate 438 each time-to-event trait (Fig. 4).

Scenario for DCCT-based complex genetic architecture – Overall, the complex genetic architecture represents multiple types of SNP-trait associations (Fig. 3): direct association with each T1DC trait (SNP2, SNP4), indirect association with both T1DC traits via measured (SNP1) and unmeasured (SNP3) longitudinal QTs; and direct and indirect association via a measured longitudinal QT (SNP5); all longitudinal risk factors exhibit within-subject random variability. Except for SNP3, all other SNP scenarios represent SNP association with a longitudinal QT risk factor (SNP1, SNP5) or a time-to-event trait (SNP2, SNP4, SNP5) testable in a single-trait GWAS.

446 SNP1, SNP3 and SNP5 have indirect effects on T1DC traits, such that their associations with the 447 T1DC traits are detectable in discovery analysis for each TTE trait, using Cox PH time-to-event 448 models fitted separately for each TTE trait and ignoring the longitudinal QT risk factors (File S2, 449 section 8). SNP1 corresponds roughly to rs10810632 and rs1358030 associations reported in the 450 motivating DCCT GWAS of HbA1c (Paterson et al. 2010), while SNP5 represents a strong signal 451 that would be detected in separate GWAS analysis of each longitudinal and time-to-event trait.

452 Analysis of the simulated data – To evaluate the statistical performance under the complex 453 genetic architecture outlined above, focusing on direct and/or indirect classification, we compare 454 extended joint model analysis of multiple longitudinal QT risk factors and multiple T1DC with 455 alternative analysis methods that do not fully exploit the data structure. These alternative 456 approaches include joint model analyses limited to two longitudinal QT and one time-to-event 457 trait, joint model analyses of one longitudinal QT and one time-to-event trait, and a conditional 458 time-to-event analysis of two time-to-event traits adjusted for observed values of two longitudinal 459 QTs. We assess the impact of model specification on the classification accuracy of direct and/or 460 indirect SNP associations by fitting mis-specified joint models that leave out important covariates 461 or traits. Altogether, the comparisons are designed to assess the merits of extended joint model 462 analysis over simpler available methods. In each replicated dataset, each of the five SNPs is 463 separately analysed for association with the longitudinal QTs and TTE traits, using four alternative 464 analytic approaches:

465 466

467

• JM-cmp: a *completely* specified joint model analysis that includes observed (HbA1c, SBP) and unobserved (*U*) longitudinal QT as well as baseline covariates (sex, T1D duration) used in the data simulation. Due to the latent nature of unobserved *U*, JM-cmp cannot be

468 fitted in practice, but we include it as a benchmark for comparison against the data analysis
469 models JM-mis that are fitted without *U*.

- JM-mis: includes the same variables as in JM-cmp, but excludes U, the unobserved
 longitudinal QT.
- 472 JM-sep: joint models of two longitudinal traits and one time-to-event trait that do not 473 account for dependency between the time-to-event traits (where JM-sep (l = 1,2; k=1)) denotes the joint model for DR; and JM-sep(l = 1,2; k=2) the joint model for DN), and 474 475 joint models of one longitudinal and one time-to-event trait that do not account for 476 dependence between the longitudinal traits, nor between the time-to-event traits (referred 477 to as JM-sep(l = 1; k=1), JM-sep(l = 1; k=2), and JM-sep(l = 2; k=2)). Altogether, the JM-478 sep models assess the merits of the extended joint model methods in comparison to JM-479 mis and JM-cmp.

480 CM-obs: a Cox PH frailty survival analysis of both time-to-event traits (DR, DN) that 481 includes the same variables as in JM-mis but adjusts for the observed longitudinal QT 482 values as time-dependent covariates; this model corresponds to the conditional analysis 483 approach mentioned above. Here, to classify SNPs as indirect association, we fit a linear 484 mixed model for both QTs to test the SNP effects on the QT(s) adjusted for the same 485 covariates as used for the joint models. Comparisons of estimation, hypothesis testing, and 486 classification results based on CM-obs to those based on JM-mis and JM-cmp allow us to 487 assess the impact of within-subject QT variation/measurement errors on hypothesis testing 488 and classification results for each SNP.

489 For each of these analyses, we compute empirical covariance matrices for the effect estimates
490 using 500 bootstrap iterations and construct large sample test statistics for each of the SNP effect

491 parameters. Under two-stage JM inference, in stage 1 we fit a bivariate (l=1,2) or univariate (l=1492 or l=2) longitudinal QT model and test the $\beta_{g,l}$ parameters for indirect SNP association. Then in 493 stage 2, we fit the time-to-event models with the QT trajectories from stage 1 according to the TTE 494 model specification (k=1,2; k=1, or k=2), and test the $\gamma_{g,k}$ parameters for direct SNP association. 495 Because stage 1 QT analysis is shared among methods, differences in classification among analytic 496 methods largely arise through differences in the test results in stage 2 TTE analysis.

497 Under two-stage and conditional independence assumptions described in an Appendix, the SNP 498 association estimates of $\beta_{g,l}$ and $\gamma_{g,k}$ and corresponding test statistics are expected to be 499 uncorrelated under the *global null* scenario, but this may not necessarily hold under the *genetic* 500 *alternative* scenario when the analysis model is mis-specified or when the time-to-event estimation 501 uses observed longitudinal trait values. We therefore compute empirical correlations in each 502 replicate under both scenarios.

503 Given hypothesis test results for a pair of QT/TTE traits for each SNP, we apply the procedure 504 defined in Table 1 to classify the SNP-TTE association.

Evaluation criteria – We compare type I error and power of hypothesis tests of SNP-QT ($\beta_{g,l}$) and SNP-TTE ($\gamma_{g,k}$) association among the alternative analytic approaches (JM-cmp, JM-mis, JMsep, CM-obs) under the *global null* and *causal* genetic scenarios for each of the 5 SNPs analysed separately, at $P^* = 5\%$ and 1% critical values. We assess estimation accuracy using mean bias for $\beta_{g,l}$ and $\gamma_{g,k}$ estimates, and confidence interval coverage across replicates, and similarly examine the distribution and mean of their bootstrap standard errors and correlation for all the compared models.

512 For each of the 5 SNPs, we evaluate accuracy of the procedure presented in Table 1 to classify 513 SNP association with each of the TTE traits as direct and/or indirect. Specifically, under the global 514 null and causal genetic scenarios, we compare the empirical classification frequencies to the 515 expected classification frequencies under the assumption of indirect and/or direct association built 516 into the generating model. The empirical frequencies are tabulated from the distribution of 517 simulation replicates in the four classification categories (direct, indirect, direct and indirect, not 518 direct and not indirect) as defined in Table 1, using specified classification thresholds such that $P_{\beta}^* = P_{\gamma}^* = P^*$, with $P^*=0.05$. We calculate expected frequencies under the assumption that the Z 519 statistics, constructed from the estimates of $\beta_{g,l}$ and $\gamma_{g,k}$, and their bootstrap variances, follow a 520 521 bivariate normal distribution with correlation specified by the bootstrap estimates (see File S2, 522 section 9 for details), to allow for potential dependence between the SNP parameter tests. We judge 523 the classification procedure for a SNP association with each QT-TTE trait pair to have high 524 accuracy when the empirical frequencies are consistent with those expected, and we compare 525 accuracy among the different models. We also assess empirical classification frequencies for SNPs with non-null effects across variation in stringency of significance thresholds up to $P^*=10^{-5}$. 526

527 Availability

- 528 DCCT data are available to authorized users at <u>https://repository.niddk.nih.gov/studies/edic/</u>
- and <u>https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000086.v3.p1</u>
- 530 (IRB #07-0208-E). Example R codes for DCCT-data-based simulation and analysis of the
- 531 simulated data are provided on GitHub (<u>https://github.com/brossardMyriam/Joint-model-for-</u>
- 532 <u>multiple-trait-genetics</u>). Supplementary files are available online
- 533 (https://figshare.com/s/2b9f6b3da5e1f03e8086). File S1 includes the description of the DCCT

- dataset as well as the list of the participants of the DCCT/EDIC Research Group; File S2
- 535 includes supplemental information for the DCCT-based simulation study; File S3 includes
- 536 supplemental information for the Analysis of the DCCT Genetics Study data; File S4 includes
- 537 the list of SNPs analyzed in DCCT; File S5 includes some notes on a multi-trait SNP association
- test for SNP effects estimated under the proposed joint model framework. Computations were
- 539 run on the Niagara supercomputer (see
- 540 https://docs.computecanada.ca/wiki/Niagara#Niagara_hardware_specifications_and
- 541 <u>https://docs.scinet.utoronto.ca/index.php/Niagara_Quickstart</u> for the hardware specifications and
- 542 characteristics). Computational resources and time used to fit the joint model of two quantitative
- 543 traits (HbA1c, SBP) and two time-to-event traits (DR, DN) in DCCT for one SNP are provided
- 544 as part of the discussion section.

545 **RESULTS**

546 Simulation Study

547 SNP association test validity and power – Under the *global null* scenario of no genetic 548 association with any of the traits, the type I error of each SNP test ($\beta_{g,l}$ and $\gamma_{g,k}$) is reasonably well 549 controlled (Table 2, left-hand side), and the *P*-values P_{β_g} and P_{γ_g} from the joint models show no 550 departure from the expected large sample distributions (χ^2 with 1 degree of freedom, see section 551 7 in File S2).

552 Under the alternative multi-SNP *causal genetic* scenario (Table 2, right-hand side), type I errors 553 for tests of each null $\beta_{g,l}$ tend to be close to the nominal level of 5% for most analysis models (with 554 exceptions for SNP2 and SNP5), while tests of the two SNPs with effects on intermediate

555 measured longitudinal QT risk factors (SNP1 ($\beta_{g,1}$) and SNP5 ($\beta_{g,2}$)) reach 100% power for all the analysis models (Table 2, right-hand side). Tests of null $\gamma_{g,k}$ by JM-cmp, JM-mis and JM-556 557 sep(l=1,2; k, with k=1 or 2) show overall good type I error control for all SNPs with direct and/or 558 indirect effects via measured longitudinal QTs (i.e. all SNPs but SNP3). However, for SNP1 with 559 indirect effects on both T1DC traits via HbA1c, tests of null $\gamma_{g,2}$ exhibit liberal type I errors in JM-560 sep(l=2; k=2), which may be explained by bias in SNP1 effect on DN ($\gamma_{g,2}$, see File S2, section 561 6) towards the indirect SNP1 effect via HbA1c QT risk factor, which is ignored from JM-sep(l=2; 562 k=2). For SNP2 which has direct effect on DR ($\gamma_{g,1}$), tests of non-null $\gamma_{g,1}$ exhibit equivalent or 563 higher power under JM-cmp and JM-mis (closely followed by JM-sep(l=1,2; k)). However, the 564 power to detect the direct SNP4 effect on DN ($\gamma_{g,2}$) appears reduced in JM-sep(*l*=1; *k*=2); which can be explained by the bias in $\widehat{\gamma_{g,2}}$ towards the null, due to ignoring SBP QT risk factor in JM-565 sep(l=1; k=2). For SNP5 with direct and indirect effects on DN via SBP, $\gamma_{g,2}$ appears detected by 566 567 a larger number of replicates under JM-sep(l=1; k=2) and CM-obs (Table 2, right-hand side); which may be explained by bias in SNP5 effect ($\hat{\gamma_{g,2}}$, see File S2, section 6) towards the overall 568 569 SNP5 effect (combining direct and indirect SNP5 effects via SBP), given that SBP is ignored from 570 JM-sep(l=1; k=2) and random SBP variation in CM-obs. Finally, for SNP3 that has indirect effects 571 on both T1DC traits via the unmeasured longitudinal risk factor U, only JM-cmp accounts for indirect SNP3 pathways via U. This translates into elevated type I errors for tests of each null $\gamma_{g,k}$ 572 likely explained by the biased SNP3 effects on both T1DC traits ($\hat{\gamma}_{g,k}$, see File S2, section 6) in 573 574 JM-mis, all JM-sep, and CM-obs, towards the indirect SNP3 effect via U. Overall, the relative 575 ranking of empirical powers among the analysis models persists for tests of each $\gamma_{g,k}$ across P^* varying up to 10⁻⁵ (File S2, section 8), with steeper power reduction for detection of SNP4 effect 576

577 on DN ($\gamma_{g,2}$) in JM-sep(l=1; k=2), and markedly misleading detection of SNP5 effect on DN ($\gamma_{g,2}$) 578 in JM-sep(l=1; k=2) and CM-obs.

As noted above, the improvement of the type I errors control and powers in tests of each $\gamma_{a,k}$ under 579 the alternative simulation scenario by JM-cmp (closely followed by JM-mis and JM-sep(l=1,2; 580 581 k=1 or 2)) compared to JM-sep(l=1 or 2; k=1 or 2) for one longitudinal and one time-to-event trait and CM-obs can be explained by more efficient estimation accuracy in $\widehat{\gamma_{g,k}}$, but also in the QT 582 effect estimates on the TTE $(\widehat{\alpha_{l,k}})$ as illustrated by: bias reduction, coverage probabilities closer to 583 584 the nominal level (95%), and empirical 95% confidence intervals of the parameter estimates 585 narrower around the true parameter (File S2, section 6). Moreover, we find little evidence for correlation between $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$. The average bootstrap correlation $\widehat{\rho_{l,k}}$ across replicates is low 586 for each QT/TTE trait pair (l; k) under the alternative genetic (Tables 3-7) and global null scenarios 587 (File S2, section 9) for all joint model analyses ($|\hat{\rho_{l,k}}| < 0.05$). However, we see larger $|\hat{\rho_{l,k}}|$ 588 589 values in CM-obs, particularly for the SBP/DN trait pair; this may be explained by larger random 590 variation in SBP which is ignored by CM-obs.

591 Classification of direct and/or indirect SNP associations with time-to-event traits –

592 Under the *global null* scenario, the empirical classification frequencies for direct and/or indirect 593 SNP association with each T1DC trait at significance level $P^* = 0.05$ agree with the expected 594 classification frequencies for all the categories of SNP associations and for all the models (File S2, 595 section 9); this observation confirms the accuracy of the proposed hypothesis procedure under the 596 *global null* genetic scenario. We also find the expected classification frequencies to be insensitive 597 to larger bootstrap correlation values ($|\hat{\rho_{l,k}}| < 0.4$, see File S2, section 9). Overall, empirical and

expected classification frequencies are close to the nominal rate of 5% for the categories of direct or indirect association, but conservative for the category of direct and indirect association (see File S2, section 10); which requires rejection of single-parameter hypothesis for the two tests of SNP effects $\beta_{g,l}$ and $\gamma_{g,k}$ (Table1).

602 Under the *alternative* simulation scenario, when SNPs have direct and/or indirect effects via 603 measured longitudinal QTs, we find that the proposed multivariate joint models, JM-cmp, JM-mis 604 (and JM-sep(l=1,2; k with k=1 or 2)) lead to improved classification accuracy (empirical 605 classification frequencies closer to the expected ones for each of the four categories of association) 606 at specified significance level $P^* = 0.05$, and correctly classify the simulated SNP associations for 607 each trait pair in more than 88% of replicates for SNP1, SNP2 and SNP4 (Tables 3 to 5), and in 608 more than 61% of replicates for SNP5 (Table 6). In contrast, JM-sep(l=1 or 2; k=1 or 2) and CM-609 obs models exhibit larger differences between empirical and expected classification frequencies, 610 which suggests lower ability of these models to correctly distinguish between direct and/or indirect 611 association; which can lead to misleading inference. This is especially the case for the SNPs with bias in $\widehat{\gamma_{q,k}}$ and low type I error control or power for test of $\widehat{\gamma_{q,k}}$ in JM-sep(l=1 or 2; k=1 or 2) and 612 613 CM-obs models, as illustrated for:

SNP1 that has indirect association with both T1DC traits via HbA1c; it exhibits lower than-expected empirical classification frequencies for the correct association category
 with HbA1c/DR (indirect association) and with SBP/DN (not direct and not indirect
 association), see Table 3;

SNP4 that has a direct association with DN, with lower than expected empirical
 classification frequency for the correct direct association category with HbA1c/DN in JM sep(*l*=1; *k*=2) as shown in Table 5;

SNP5 with direct and indirect effects on DN via SBP, which exhibit larger than expected
 empirical classification frequencies for the correct association category with HbA1c/DN
 (direct association), and with SBP/DN (direct and indirect association), see Table 6.

On the other hand, for SNP3 which has indirect effects on both T1DC traits via the unmeasured longitudinal QT risk factor (U); except JM-cmp which exhibits accurate (and high) classification frequencies, all the other compared models (which ignore U), exhibit poor classification accuracy (Table 7) and tend to mistakenly classify SNP3 as a direct association with each T1DC trait in ~30-86% of the replicates.

As stringency of P^* increases up to 10^{-5} for the same effect sizes, empirical classification frequencies decrease in the correct association category, while mis-classification frequencies increase in the other categories; for example SNP5 tends to be mistakenly classified as an indirect association with SBP/DN with JM-cmp (File S2, section 11).

633 In summary, our simulations show that by using smoothed trajectories and accounting for all OT 634 associations, the extended joint model improves parameter estimation efficiency and classification 635 accuracy of SNPs directly associated with each time-to-event trait or indirectly associated via a 636 measured longitudinal QT in comparison to classification using JM-sep models for analysis of 637 each time-to-event trait with one or multiple longitudinal traits or CM-obs. Reduced classification 638 accuracy translate to increased risk of misclassifying a SNP as direct and/or indirect association. 639 In addition, when a SNP has both direct and indirect effects on a time-to-event trait, the proposed 640 classification procedure can be conservative because it requires the joint significance of the two SNP effects, $\beta_{q,l}$ and $\gamma_{q,k}$, where the power of each test depends on effect size, MAF and trait 641 642 distribution. As a result, a SNP with both direct and indirect associations can be misclassified as

643 either a direct or an indirect association, as we will also illustrate in the application results in 644 DCCT. Finally, when a SNP has an indirect effect on both T1DC traits via an unmeasured QT, the 645 testing procedure based on JM-mis, that captures some of the unmodeled dependency between 646 time-to-event traits through the frailty term, does not prevent misclassification as a direct 647 association, which could be due to the limitation of using a time-invariant frailty term. In addition, 648 this observation also demonstrates the importance of the proposed joint model extension, which 649 allows analysis on all the intermediate QT(s), as opposed to JM-sep, to avoid misclassification of 650 direct and/or indirect SNP associations.

651 Application in the DCCT Genetics Study data

652 We demonstrate feasibility of the proposed two-stage extended joint model method by analysis in 653 the DCCT Genetics Study data. The application is based on DCCT individuals from the 654 Conventional treatment group genotyped on HumanCoreExome Bead Array (Illumina, San Diego, 655 CA, USA) with ungenotyped autosomal SNPs imputed using 1000 Genomes data phase 3 (The 656 1000 Genomes Project Consortium 2015), as detailed in File S1. We use time to mild retinopathy 657 and time to persistent microalbuminuria, for DR and DN outcomes respectively, as previously 658 defined in the motivating GWAS of HbA1c (Paterson et al. 2010); see File S3, section 1 for details. 659 Out of 667 conventionally-treated DCCT individuals with genetic data, we analyze N=516660 subjects, excluding those with mild to moderate non-proliferative retinopathy or DN at DCCT 661 baseline. By the time of the DCCT close-out visit, 297 (57.6%) had a DR event, and 61 (11.8%) 662 had a DN event, including 47 subjects (9.1%) that experienced both events. After SNP filtering 663 and pruning on linkage disequilibrium (File S3, section 2), we analyze 307 SNPs reported as 664 associated with HbA1c, SBP, or multiple definitions of DR and/or DN (Paterson et al. 2010; Grassi

et al. 2011; Sandholm et al. 2012; Hosseini et al. 2015; Wheeler et al. 2017; Evangelou et al. 2018;
Pollack et al. 2019), see File S4 for the full list of SNPs.

667 **Joint model fitting** – We fit the joint model for each SNP one at a time, including baseline 668 covariates (age at diagnosis, T1D duration, cohort, sex, and year of DCCT study entry), 669 longitudinal HbA1c and SBP, and T1DCs DR and DN (File S3, section 3). Given prior evidence 670 for long term HbA1c effects on T1DC, we present results under the time-weighted cumulative for 671 HbA1c association with time-to-T1DC traits, which exhibits stronger prior association with T1DC 672 in the DCCT individuals analyzed here, but we obtained similar classification results under the 673 two alternative specifications considered for HbA1c association (i.e. contemporaneous value and 674 updated mean, see File S3, section 4). We apply diagnostic tools in the joint model analysis, 675 including residual analysis in the longitudinal and time-to-event sub-models, finding little 676 evidence for model misspecification (File S3, section 5). In the Cox PH frailty time-to-event sub-677 model, PH assumptions are well-satisfied when the baseline hazard is stratified on the cohort 678 variable; overall conclusions are equivalent when cohort is included as a covariate. As shown in 679 File S3 (section 5), the martingale residuals of the Cox PH frailty model are consistent with the 680 assumption of a linear relationship between the QTs and each time-to-T1DC outcome.

In Fig. 5 (Panel A), we show that rs1358030 and rs10810632, which were discovered in a previous GWAS of HbA1c in DCCT (Paterson et al. 2010), are classified as indirect associations with both T1DC traits via their association with the HbA1c shared risk factor ($P_{\beta_g} \le P^*$ and $P_{\gamma_g} > P^*$, $P^*=1.7 \times 10^{-4}$ after Bonferroni correction for the 289.02 effective SNPs tested (Li and Ji 2005)). Although the other candidate SNPs were selected from larger meta-analysis in T1D and/or independent studies in general populations (Paterson et al. 2010; Grassi et al. 2011; Sandholm et

al. 2012; Hosseini et al. 2015; Wheeler et al. 2017; Evangelou et al. 2018; Pollack et al. 2019), the
SNP-trait association tests did not reach Bonferroni-corrected significance thresholds in our
analysis (File S3, section 4), potentially due to effect heterogeneity and low power to detect these
variants or by some inherent heterogeneity factors in the study designs and/or phenotypic
definitions. Thus, classification for these candidate SNPs is uninformative.

692 **Sample size and power considerations** – The DCCT-based simulation study shows that multiple-693 trait joint model analysis can achieve high classification rates for direct and/or indirect SNP 694 associations under SNP effect sizes in the specified range (SNP effects: on the QTs 0.7-7, on T1DC 695 0.4-0.8; and MAFs 10-40%) and classification rates under the global null hypothesis (null SNP 696 effects on all traits) controlled to the nominal levels for direct or indirect SNP association but 697 conservative for direct and indirect association. Compared to the simulation, the number of DN 698 events is lower in the DCCT data application. We thus expect lower power to detect direct SNP 699 association with DN; this implies reduced accuracy to classify a SNP as having either a direct, or 700 a direct and indirect association.

In light of the simulation results, we acknowledge that a larger sample size would be required to maintain performance in DCCT for genetic associations with lower MAFs/effect sizes than the ones specified. In particular, lower effect sizes and MAFs can lead to larger variances of estimated effects and larger 95% confidence intervals, as observed for the direct effects of rs10810632 (MAF=7%) compared to rs1358030 (MAF=36%) for both time-to-T1DC traits (Fig. 5, Panels B and C). SNP effects with larger variances have lower power to detect association. Although we expect the effect sizes estimated by the joint model to be relatively insensitive to the study sample

size, reduction in variances by increasing study sample size would be expected to improve
classification accuracy for these two SNPs (particularly for rs10810632 that has a lower MAF).

710 To assess how genetic association and classification results for rs10810632 and rs1358030 may be 711 affected by increasing sample size, we applied parametric resampling (see File S3, section 6 for 712 details) to draw datasets with sample size up to five times the DCCT sample of N=516, and we 713 then extrapolated the classification beyond N=2580. This analysis demonstrates decreasing 714 variances of the SNP effects for both SNPs as sample size increases and narrowing of the 95% and 715 99% confidence intervals (File S3, section 6); panel A in Fig. 6 illustrates the corresponding shift 716 in classification of rs10810632 association with DR as indirect via HbA1c towards classification 717 as both indirect and direct. On the other hand, given that both SNPs were previously discovered in a GWAS of HbA1c in DCCT, SNP effect estimates for HbA1c association ($\widehat{\beta_{g,1}}$) may be 718 719 overestimated due to Winner's curse bias (Kraft 2008; Sun et al. 2011), which would impact the 720 classification results. We therefore repeated the sample size analyses specifying an adjusted SNP 721 effect size for the HbA1c association equal to 50% of its effect estimate in our DCCT analysis. In 722 this scenario the test of SNP association with HbA1c falls just below the P^* threshold in the 723 resample size N=516, although power improves in larger sample sizes (Fig. 6). Here again 724 classification tends to shift from indirect towards both direct and indirect SNP associations with 725 both T1DC traits (see File S3, section 6 for complete results for both SNPs); however, a much 726 larger sample size is needed to cross the *P** threshold for test of direct association.

727 In the DCCT application, we take advantage of the largest available clinical study of T1D 728 complications with long-term follow-up and high-density longitudinal QT measurements. This 729 highlights the dearth of longitudinal studies with both a large number of individuals and long-term

730 clinical follow-up, as well as the related challenges in joint model analysis. In prospective study 731 designs with both longitudinal and time-to-event traits, an inherent imbalance can exist among 732 traits in detection of SNP associations, in that power for QT(s) depends on the number of 733 measurements while power for time-to-event traits depends on the number of events and duration 734 of follow-up. Although there is currently a trade-off between epidemiological studies with large 735 sample sizes but low density of longitudinal measurements, and clinical studies with more modest 736 sample sizes but high measurement densities, we anticipate informative application of joint model 737 analysis in large biobanks, for example (Scholtens et al. 2015; Bycroft et al. 2018; Dummer et al. 738 2018), now assembling longitudinal measures jointly with binary outcomes and genetic data.

739 **DISCUSSION**

740 We present new, more informative methods for statistical genetic analysis under a joint model 741 specification of multiple longitudinal risk factors and multiple time-to-event traits, designed to 742 characterize the complex genetic architecture of related traits in longitudinal studies of disease 743 progression. The proposed extended model is formulated to deal with dependencies within and 744 between traits and can account for trait-specific and shared covariates, within-subject random 745 variability in the longitudinal traits, as well as effects of unobserved baseline confounding factors 746 between the time-to-event traits through a subject-specific frailty term. We also introduce a 747 realistic data-based simulation algorithm to assess joint model performance that can also be used 748 to estimate achievable power in clinical studies such as DCCT characterized by extensive 749 longitudinal follow-up but limited sample size.

750 Evaluation by realistic simulation study of complex T1DC genetic architecture shows that 751 accounting for trait dependencies and measurement errors in longitudinal QT risk factors using the 752 proposed joint model extension improves classification accuracy of SNP as direct and/or indirect 753 association compared to (i) separate joint model analysis of each time-to-event trait with one or 754 multiple longitudinal traits, and (ii) Cox-PH frailty model analysis adjusted for multiple observed 755 longitudinal trait values. This improvement in classification accuracy under the joint models of 756 multiple longitudinal and multiple TTE traits results from improved Type I error control for singleparameter tests of each of the two SNP effects ($\beta_{g,l}$ or $\gamma_{g,k}$), and improved power to detect SNP 757 758 association, that can be explained by reduced estimation bias in parameters. However, we also 759 observe that estimation bias and misclassification can be severe in the presence of SNP association 760 with a longitudinal risk factor that is unmeasured or absent from the joint model, and mis-761 classification may be non-negligible when the study has limited power to detect either of the two SNP effects ($\beta_{a,l}$ or $\gamma_{a,k}$), as in the DCCT study. We apply parametric resampling to evaluate how 762 763 study sample size or Winner's curse bias affects classification accuracy and anticipate that this 764 approach may also help inform replication study design with sufficient power. Nevertheless, we 765 conclude that application of joint model analysis in longitudinal studies of disease progression, 766 such as in the DCCT Genetics Study, improves classification of direct and/or indirect SNP 767 association and helps to elucidate the genetic architecture of complex traits.

Although the primary aim in this report is to develop statistical methods to distinguish among direct and/or indirect SNP associations with each time-to-event trait, the multi-trait extension of the joint model lends itself to development of multi-trait SNP association testing for SNP discovery. In File S5, we present a joint-parameter test for global SNP association with all the longitudinal and time-to-event traits, based on a generalized Wald statistic. In application to the

simulated DCCT-based complex genetic architecture, we observe good type I error control under
the global genetic null scenario, improved power for SNP discovery when a SNP has multiple trait
effects, and power maintenance in other SNP association scenarios.

776 Although the extended joint model can be applied to studies where longitudinal QT measurements 777 are missing at some of the visits, choice of the joint model estimation method depends on the 778 missing data mechanism. In the presence of informative missing data mechanisms, we recommend 779 sensitivity analysis using existing implementations of joint likelihood estimation that assume the 780 time-to-dropout mechanism depends on missing longitudinal QT values through the posterior 781 distribution of the random effects; this corresponds to an informative missing data mechanism 782 (Rizopoulos 2012). To our knowledge these implementations exist only for simple joint model 783 formulations with either one longitudinal and one time-to-event trait (Rizopoulos 2010) or with 784 multiple longitudinal traits and one time-to-event outcome (Rizopoulos 2016; Hickey et al. 2018c). 785 Alternatively multiple imputation methods have been implemented for two-stage estimation 786 (Rubin 1987; Moreno-Betancur et al. 2018); these impute missing values for multiple longitudinal 787 continuous traits using the conditional distribution of each QT trait given one time-to-event trait 788 and other QTs. More generally for missing data, further development of methods to maximize the 789 extended joint likelihood, for example using Bayesian methods, would alleviate numerical 790 challenges with increasing model complexity in multivariate extensions of joint models (Lawrence 791 Gould et al. 2015); but this would require the design of an efficient sampling algorithm to study 792 the posterior distribution.

We acknowledge several features of the joint model approach that warrant examination in further
work. *Firstly*, to reduce computational complexity and improve model flexibility, we use two-

795 stage parameter estimation. In some circumstances, this approach can produce biased estimates in 796 the longitudinal and/or time-to-event sub-models as well as underestimation of their standard 797 errors (Tsiatis et al. 1995; Wulfsohn and Tsiatis 1997; Dafni and Tsiatis 1998; Ye et al. 2008; 798 Albert and Shih 2010; Sweeting and Thompson 2011; Ye and Wu 2017; Huong et al. 2018; Mauff 799 et al. 2020). Biased estimates can result from informatively missing data in the presence of non-800 random censoring of the longitudinal trait values due to the occurrence of an event or from 801 informative dropout (Ye et al. 2008; Albert and Shih 2010; Mauff et al. 2020). The simulation 802 results show minimal biases in the absence of informative censoring, even when an associated 803 longitudinal QT variable is omitted from the joint model. In the DCCT application, characterized 804 by administrative censoring and a high completion rate, these biases are of less concern because 805 longitudinal trait values continued to be recorded on a pre-specified visit schedule regardless of 806 the occurrence of any T1DC events; we estimated the trajectories using all the available 807 measurements. Furthermore, we obtain robust non-parametric bootstrap estimates of the 808 covariance matrix for the SNP effects, and simulation results under the null do not show deviation 809 from expected distributions. Secondly, because the joint model integrates longitudinal and time-810 to-event sub-models, model misspecification can occur in multiple ways and lead to invalid 811 inference (Arisido et al. 2019). We recommend a careful assessment of model assumptions and 812 data-based simulation studies to evaluate the robustness of classification of direct and/or indirect 813 associations to two-stage assumptions. In the DCCT application, we provide an illustration of 814 diagnostic analyses which could serve as guidance in other applications. *Thirdly*, patient visits 815 were scheduled with high frequency in DCCT, so we ignored the modest degree of interval 816 censoring in the current implementation of the joint model; when there are longer gaps between

817 visits, extended methods are needed to account for interval censoring in the time-to-event sub-

818 model with additional simulation studies to assess impact on joint model estimates.

819 *Computationally*, joint model fitting can be very demanding, particularly for genetic association 820 studies that test millions of variants. In the DCCT application, it took ~1 minute to fit the joint 821 model for each SNP and ~ 18 more minutes to estimate the covariance matrix with 500 bootstraps 822 run in parallel on 4 nodes (each node with 40 CPU and 202 GB RAM). While analysis at the 823 genome-wide level, involving for example ~9 million imputed autosomal SNPs in DCCT Study 824 (Roshandel et al. 2018), is computationally unrealistic at present, a screening approach without 825 bootstrap to select informative SNPs, followed by bootstrap refinement would reduce the 826 computational burden to feasible levels. Recently, computationally efficient algorithms have been 827 developed to improve feasibility of linear mixed model (Sikorska et al. 2018) and Cox PH model 828 (Rizvi et al. 2019; Bi et al. 2020) analyses for genome-wide genetic association studies, but to 829 date, they remain to be implemented for multivariate outcomes. Lastly, (Liu et al. 2018) discuss 830 various formulations and interpretations of joint models in the context of mediation analysis, with 831 shared-random-effects accounting for potential unmeasured baseline confounding factors between 832 one longitudinal and one time-to-event traits. Using applications in datasets from two clinical 833 trials, they illustrate interpretation of sensitivity analysis to unmeasured baseline confounders. 834 Adaptation of the joint model we propose for multiple longitudinal and multiple time-to-event 835 traits for mediation analysis requires extension of the mediation assumptions (Sobel 1982; 836 Mackinnon et al. 1995) to the case of multiple mediators and multiple time-to-event traits. Specific 837 evaluations of the proposed model under these assumptions are also warranted.

838 We expect application of joint model methods in large biobank datasets to be informative in 839 characterization of the genetic architecture of complex traits. Some extensions of joint models 840 have been proposed to account for additional challenges raised by large biobanks, for example 841 informative visiting processes (Gasparini et al. 2020). By providing more efficient SNP effect 842 estimates and increased precision in polygenic risk score development, results of such analysis 843 have potential to contribute to the translation of human genetic findings into personalized medicine 844 (Young et al. 2019), as well as to causal inference using mediation and mendelian randomization 845 studies. Finally, the joint model framework has potential to enable dynamic prediction beneficial 846 for dynamic risk assessment (Papageorgiou et al. 2019; Bull et al. 2020) and optimization of 847 intervention strategies (Sweeting and Thompson 2011; Yuen et al. 2018).

848 Acknowledgements

849 This study uses data provided by the Diabetes Control and Complications Trial / Epidemiology of 850 Diabetes Interventions and Complications (DCCT/EDIC) Research Group which is sponsored 851 through research contracts from the National Institute of Diabetes, Endocrinology and Metabolic 852 Diseases of the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) and the 853 National Institutes of Health (NIH). The authors are grateful to the subjects in the DCCT/EDIC 854 cohort for their long-term participation. A complete list of the individuals and institutions 855 participating in the DCCT/EDIC Research Group can be found in File S1. This project was 856 supported by: CIHR Operating/Project Grants (#MOP-84287, #PJT-159509, #PJT-159463), 857 CANSSI Collaborative Research Team in "Statistical methods for the analysis of genetic data with 858 survival outcomes", CANSSI postdoctoral fellowship (MB), CIHR STAGE fellowships (MB and 859 OEG, #GET-101831). Computations were performed on the Niagara supercomputer at the SciNet 860 HPC Consortium. SciNet is funded by the Canada Foundation for Innovation under the auspices

- 861 of Compute Canada; the Government of Ontario; Ontario Research Fund Research Excellence;
- and the University of Toronto.

863 Abbreviations

- 864 DAG: directed acyclic graph;
- 865 DCCT: Diabetes control and complications trial;
- 866 DR: diabetic retinopathy;
- 867 DN: diabetic nephropathy;
- 868 GWAS: genome-wide association study;
- 869 HbA1c: Hemoglobin A1c;
- 870 LD: linkage disequilibrium;
- 871 MAF: minor allele frequency;
- 872 PH: proportional hazards;
- 873 QT(s): quantitative trait(s);
- 874 SBP: systolic blood pressure;
- 875 SNP: single nucleotide polymorphism;
- 876 T1DC: type 1 diabetes complications;
- 877 TTE: time-to-event.

878 Literature cited

- Albert PS, Shih JH. 2010. On estimating the relationship between longitudinal measurements
- and time-to-event data using a simple two-stage procedure. Biometrics. 66(3):983–991.
- doi:10.1111/j.1541-0420.2009.01324_1.x. https://about.jstor.org/terms.
- 882 Arisido MW, Antolini L, Bernasconi DP, Valsecchi MG, Rebora P. 2019. Joint model robustness
- 883 compared with the time-varying covariate Cox model to evaluate the association between a
- longitudinal marker and a time-to-event endpoint. BMC Med Res Methodol. 19(1):222.
- doi:10.1186/s12874-019-0873-y. http://www.ncbi.nlm.nih.gov/pubmed/31795933.
- Asar Ö, Ritchie J, Kalra PA, Diggle PJ. 2015. Joint modelling of repeated measurement and
- time-to-event data: An introductory tutorial. Int J Epidemiol. 44(1):334–344.
- 888 doi:10.1093/ije/dyu262.
- 889 Bi W, Fritsche LG, Mukherjee B, Kim S, Lee S. 2020. A fast and accurate method for genome-
- 890 wide time-to-event data analysis and its application to UK Biobank. Am J Hum Genet.
- 891 107(2):222–233. doi:10.1016/j.ajhg.2020.06.003. https://doi.org/10.1016/j.ajhg.2020.06.003.
- 892 Brent RP. 2013. Algorithms for minimization without derivatives. Courier Co.
- 893 Brown ER, Ibrahim JG. 2003. A Bayesian semiparametric joint hierarchical model for
- 894 longitudinal and survival data. Biometrics. 59(2):221–8. doi:10.1111/1541-0420.00028.
- 895 http://www.ncbi.nlm.nih.gov/pubmed/12926706.
- 896 Bull L, Lunt M, Martin G, Hyrich K, Sergeant J. 2020. Harnessing repeated measurements of
- 897 predictor variables for clinical risk prediction: a review of existing methods. Diagnostic Progn

- 898 Res. 4(1):1–16. doi:10.1186/s41512-020-00078-z.
- 899 Bycott P, Taylor J. 1998. A comparison of smoothing techniques for CD4 data measured with
- 900 error in a time-dependent Cox proportional hazards model. Stat Med. 17(18):2061–77.
- 901 doi:10.1002/(sici)1097-0258(19980930)17:18<2061::aid-sim896>3.0.co;2-o.
- 902 http://www.ncbi.nlm.nih.gov/pubmed/9789914.
- 903 Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
- 904 Delaneau O, O'Connell J, et al. 2018. The UK Biobank resource with deep phenotyping and
- 905 genomic data. Nature. 562(7726):203–209. doi:10.1038/s41586-018-0579-z. [accessed 2019 Aug
- 906 6]. http://www.nature.com/articles/s41586-018-0579-z.
- 907 Chen LM, Ibrahim JG, Chu H. 2011. Sample size and power determination in joint modeling of
- 908 longitudinal and survival data. Stat Med. 30(18):2295–2309. doi:10.1002/sim.4263.
- 909 Crowther MJ, Lambert PC. 2013. Simulating biologically plausible complex survival data. Stat
- 910 Med. 32(23):4118–4134. doi:10.1002/sim.5823.
- 911 Dafni UG, Tsiatis AA. 1998. Evaluating surrogate markers of clinical outcome when measured
- 912 with error. Biometrics. 54(4):1445–1462. doi:10.2307/2533670. [accessed 2019 Jul 12].
- 913 https://www.jstor.org/stable/2533670?origin=crossref.
- 914 Deng Y, Pan W. 2017. Conditional analysis of multiple quantitative traits based on marginal
- 915 GWAS summary statistics. Genet Epidemiol. 41(5):427–436. doi:10.1002/gepi.22046.
- 916 https://onlinelibrary.wiley.com/doi/10.1002/gepi.22046.
- 917 Dummer TJB, Awadalla P, Boileau C, Craig C, Fortier I, Goel V, Hicks JMT, Jacquemont S,

- 918 Knoppers BM, Le N, et al. 2018. The Canadian Partnership for Tomorrow Project: A pan-
- 919 Canadian platform for research on chronic disease prevention. Cmaj. 190(23):E710–E717.
- 920 doi:10.1503/cmaj.170292.
- 921 Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou
- 922 N, Cabrera CP, Karaman I, et al. 2018. Genetic analysis of over 1 million people identifies 535
- new loci associated with blood pressure traits. Nat Genet. 50(10):1412–1425.
- 924 doi:10.1038/s41588-018-0205-x. http://www.ncbi.nlm.nih.gov/pubmed/30224653.
- 925 Faucett CL, Thomas DC. 1996. Simultaneously modelling censored survival data and repeatedly
- 926 measured covariates: a Gibbs sampling approach. Stat Med. 15(15):1663–85.
- 927 doi:10.1002/(SICI)1097-0258(19960815)15:15<1663::AID-SIM294>3.0.CO;2-1.
- 928 http://www.ncbi.nlm.nih.gov/pubmed/8858789.
- 929 Furgal AKC, Sen A, Taylor JMG. 2019. Review and comparison of computational approaches
- 930 for joint longitudinal and time-to-event models. Int Stat Rev. 87(2):insr.12322.
- 931 doi:10.1111/insr.12322. [accessed 2019 Jul 11].
- 932 https://onlinelibrary.wiley.com/doi/abs/10.1111/insr.12322.
- 933 Gasparini A, Abrams KR, Barrett JK, Major RW, Sweeting MJ, Brunskill NJ, Crowther MJ.
- 934 2020. Mixed-effects models for health care longitudinal data with an informative visiting
- 935 process: A Monte Carlo simulation study. Stat Neerl. 74(1):5–23. doi:10.1111/stan.12188.
- 936 Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. 2011. Genome-wide
- 937 meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 20(12):2472–2481.
- 938 doi:10.1093/hmg/ddr121.

- 939 Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2016. Joint modelling of time-to-
- 940 event and multivariate longitudinal outcomes: recent developments and issues. BMC Med Res
- 941 Methodol. 16(1):117. doi:10.1186/s12874-016-0212-5. http://dx.doi.org/10.1186/s12874-016-
- 942 0212-5.
- 943 Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2018a. Joint models of
- 944 longitudinal and time-to-event data with more than one event time outcome: A review. Int J
- 945 Biostat. 14(1). doi:10.1515/ijb-2017-0047.
- 946 https://www.degruyter.com/document/doi/10.1515/ijb-2017-0047/html.
- 947 Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2018b. A comparison of joint
- 948 models for longitudinal and competing risks data, with application to an epilepsy drug
- randomized controlled trial. J R Stat Soc Ser A Stat Soc. 181(4):1105–1123.
- 950 doi:10.1111/rssa.12348. [accessed 2023 Mar 24].
- 951 https://academic.oup.com/jrsssa/article/181/4/1105/7072031.
- Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. 2018c. joineRML: a joint model
- and software package for time-to-event and multivariate longitudinal outcomes. BMC Med Res
- 954 Methodol. 18(1):50. doi:10.1186/s12874-018-0502-1. [accessed 2019 Apr 23].
- 955 https://bmcmedresmethodol.biomedcentral.com/articles/10.1186/s12874-018-0502-1.
- Hogan JW, Laird NM. 1998. Increasing efficiency from censored survival data by using random
- 957 effects to model longitudinal covariates. Stat Methods Med Res. 7(1):28–48.
- 958 doi:10.1177/096228029800700104.
- 959 http://journals.sagepub.com/doi/10.1177/096228029800700104.

- 960 Hosseini SM, Boright AP, Sun L, Canty AJ, Bull SB, Klein BEK, Klein R, Paterson AD. 2015.
- 961 The association of previously reported polymorphisms for microvascular complications in a
- 962 meta-analysis of diabetic retinopathy. Hum Genet. 134(2):247–257. doi:10.1007/s00439-014-
- 963 1517-2.
- Hougaard P. 1995. Frailty models for survival data. Lifetime Data Anal. 1(3):255–273.
- 965 doi:10.1007/BF00985760. http://link.springer.com/10.1007/BF00985760.
- 966 Hsieh F, Tseng YK, Wang JL. 2006. Joint modeling of survival and longitudinal data:
- 967 Likelihood approach revisited. Biometrics. 62(4):1037–1043. doi:10.1111/j.1541-
- 968 0420.2006.00570.x.
- 969 Huong PTT, Nur D, Pham H, Branford A. 2018. A modified two-stage approach for joint
- 970 modelling of longitudinal and time-to-event data. J Stat Comput Simul. 88(17):3379–3398.
- 971 doi:10.1080/00949655.2018.1518449.
- 972 Ibrahim JG, Chen M-H, Sinha D. 2001. Joint Models for Longitudinal and Survival Data. In:
- 973 Canadian Medical Association journal. Vol. 130. p. 262–289.
- 974 http://link.springer.com/10.1007/978-1-4757-3447-8_7.
- 975 Ibrahim JG, Chu H, Chen LM. 2010. Basic concepts and methods for joint models of
- 976 longitudinal and survival data. J Clin Oncol. 28(16):2796–2801. doi:10.1200/JCO.2009.25.0654.
- 977 Jensen SM, Ritz C. 2018. A comparison of approaches for simultaneous inference of fixed
- 978 effects for multiple outcomes using linear mixed models. Stat Med. 37(16):2474–2486.
- 979 doi:10.1002/sim.7666. https://onlinelibrary.wiley.com/doi/10.1002/sim.7666.

- 980 Kraft P. 2008. Curses--winner's and otherwise--in genetic epidemiology. Epidemiology.
- 981 19(5):649–51; discussion 657-8. doi:10.1097/EDE.0b013e318181b865.
- 982 http://www.ncbi.nlm.nih.gov/pubmed/18703928.
- 983 Laird NM, Ware JH. 1982. Random-effects models for longitudinal data. Biometrics. 38(4):963–
- 984 74. http://www.ncbi.nlm.nih.gov/pubmed/7168798.
- Lawrence Gould A, Boye ME, Crowther MJ, Ibrahim JG, Quartey G, Micallef S, Bois FY. 2015.
- 986 Joint modeling of survival and longitudinal non-survival data: Current methods and issues.
- 987 Report of the DIA Bayesian joint modeling working group. Stat Med. 34(14):2181–2195.
- 988 doi:10.1002/sim.6141.
- 989 Li J, Ji L. 2005. Adjusting multiple testing in multilocus analyses using the eigenvalues of a
- 990 correlation matrix. Heredity (Edinb). 95(3):221–227. doi:10.1038/sj.hdy.6800717.
- 991 http://www.ncbi.nlm.nih.gov/pubmed/16077740.
- Lind M, Odén A, Fahlén M, Eliasson B. 1995. The Relationship of Glycemic Exposure (HbA1c)
- to the Risk of Development and Progression of Retinopathy in the Diabetes Control and
- 994 Complications Trial. Diabetes. 44(8):968–983. doi:10.2337/diab.44.8.968.
- 995 https://diabetesjournals.org/diabetes/article/44/8/968/8802/The-Relationship-of-Glycemic-
- 996 Exposure-HbA1c-to-the.
- 997 Lind M, Odén A, Fahlén M, Eliasson B. 2010. The shape of the metabolic memory of HbA1c:
- 998 Re-analysing the DCCT with respect to time-dependent effects. Diabetologia. 53(6):1093–1098.
- 999 doi:10.1007/s00125-010-1706-z.
- 1000 Liu L, Zheng C, Kang J. 2018. Exploring causality mechanism in the joint analysis of

- 1001 longitudinal and survival data. Stat Med. 37(26):3733–3744. doi:10.1002/sim.7838.
- 1002 Mackinnon DP, Warsi G, Dwyer JH. 1995. A simulation study of mediated effect measures.
- 1003 Multivariate Behav Res. 30(1):41. doi:10.1207/s15327906mbr3001_3.
- 1004 http://www.ncbi.nlm.nih.gov/pubmed/20157641.
- 1005 Mauff K, Steyerberg E, Kardys I, Boersma E, Rizopoulos D. 2020. Joint models with multiple
- 1006 longitudinal outcomes and a time-to-event outcome: a corrected two-stage approach. Stat
- 1007 Comput. 30(4):999–1014. doi:10.1007/s11222-020-09927-9.
- 1008 http://link.springer.com/10.1007/s11222-020-09927-9.
- 1009 Mauff K, Steyerberg EW, Nijpels G, van der Heijden AAWA, Rizopoulos D. 2017. Extension of
- 1010 the association structure in joint models to include weighted cumulative effects. Stat Med.
- 1011 36(23):3746–3759. doi:10.1002/sim.7385.
- 1012 Moreno-Betancur M, Carlin JB, Brilleman SL, Tanamas SK, Peeters A, Wolfe R. 2018. Survival
- 1013 analysis with time-dependent covariates subject to missing data or measurement error: Multiple
- 1014 Imputation for Joint Modeling (MIJM). Biostatistics. 19(4):479–496.
- 1015 doi:10.1093/biostatistics/kxx046. http://www.ncbi.nlm.nih.gov/pubmed/29040396.
- 1016 Papageorgiou G, Mauff K, Tomer A, Rizopoulos D. 2019. An overview of joint modeling of
- 1017 time-to-event and longitudinal outcomes. Annu Rev Stat Its Appl. 6(1):223–240.
- 1018 doi:10.1146/annurev-statistics-030718-105048.
- 1019 https://www.annualreviews.org/doi/10.1146/annurev-statistics-030718-105048.
- 1020 Paterson AD, Bull SB. 2012. Does familial clustering of risk factors for long-term diabetic
- 1021 complications leave any place for genes that act independently? J Cardiovasc Transl Res.

- 1022 5(4):388–398. doi:10.1007/s12265-012-9385-4.
- 1023 Paterson AD, Waggott D, Boright AP, Hosseini SM, Shen E, Sylvestre MP, Wong I, Bharaj B,
- 1024 Cleary PA, Lachin JM, et al. 2010. A genome-wide association study identifies a novel major
- 1025 locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes.
- 1026 59(2):539–549. doi:10.2337/db09-0653.
- 1027 Pollack S, Igo RP, Jensen RA, Christiansen M, Li X, Cheng C-Y, Ng MCY, Smith A V, Rossin
- 1028 EJ, Segrè A V, et al. 2019. Multiethnic genome-wide association study of diabetic retinopathy
- 1029 using liability threshold modeling of duration of diabetes and glycemic control. Diabetes.
- 1030 68(2):441–456. doi:10.2337/db18-0567. [accessed 2019 Oct 29].
- 1031 http://www.ncbi.nlm.nih.gov/pubmed/30487263.
- 1032 Rizopoulos D. 2010. JM : An R Package for the Joint Modelling of Longitudinal and Time-to-
- 1033 Event Data. J Stat Softw. 35(9). doi:10.18637/jss.v035.i09. http://www.jstatsoft.org/v35/i09/.
- 1034 Rizopoulos D. 2012. Joint models for longitudinal and time-to-event data. Chapman and
- 1035 Hall/CRC. https://www.taylorfrancis.com/books/9781439872871.
- 1036 Rizopoulos D. 2016. The R package JMbayes for fitting joint models for longitudinal and time-
- 1037 to-event data using MCMC. J Stat Softw. 72(7). doi:10.18637/jss.v072.i07.
- 1038 http://www.jstatsoft.org/v72/i07/.
- 1039 Rizvi AA, Karaesmen E, Morgan M, Preus L, Wang J, Sovic M, Hahn T, Sucheston-Campbell
- 1040 LE. 2019. gwasurvivr: an R package for genome-wide survival analysis. Bioinformatics.
- 1041 35(11):1968–1970. doi:10.1093/bioinformatics/bty920.
- 1042 http://www.ncbi.nlm.nih.gov/pubmed/30395168.

- 1043 Roshandel D, Gubitosi-Klug R, Bull SB, Canty AJ, Pezzolesi MG, King GL, Keenan HA, Snell-
- 1044 Bergeon JK, Maahs DM, Klein R, et al. 2018. Meta-genome-wide association studies identify a
- 1045 locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1
- 1046 diabetes. Diabetologia. 61(5):1098–1111. doi:10.1007/s00125-018-4555-9.
- 1047 http://www.ncbi.nlm.nih.gov/pubmed/29404672.
- 1048 Rubin DB, editor. 1987. Multiple imputation for nonresponse in surveys. Hoboken, NJ, USA:
- 1049 John Wiley & Sons, Inc. (Wiley Series in Probability and Statistics).
- 1050 http://doi.wiley.com/10.1002/9780470316696.
- 1051 Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ,
- 1052 Williams WW, Sadlier DM, Mäkinen V-P, et al. 2012. New Susceptibility Loci Associated with
- 1053 Kidney Disease in Type 1 Diabetes. Böger CA, editor. PLoS Genet. 8(9):e1002921.
- 1054 doi:10.1371/journal.pgen.1002921. http://www.ncbi.nlm.nih.gov/pubmed/23028342.
- 1055 Scholtens S, Smidt N, Swertz MA, Bakker SJL, Dotinga A, Vonk JM, Van Dijk F, Van Zon
- 1056 SKR, Wijmenga C, Wolffenbuttel BHR, et al. 2015. Cohort Profile: LifeLines, a three-
- 1057 generation cohort study and biobank. Int J Epidemiol. 44(4):1172–1180. doi:10.1093/ije/dyu229.
- 1058 Self S, Pawitan Y. 1992. Modeling a marker of disease progression and onset of disease. In:
- 1059 AIDS Epidemiology. Boston, MA: Birkhäuser Boston. p. 231–255.
- 1060 http://link.springer.com/10.1007/978-1-4757-1229-2_11.
- 1061 Shah A, Laird N, Schoenfeld D. 1997. A random-effects model for multiple characteristics with
- 1062 possibly missing data. J Am Stat Assoc. 92(438):775. doi:10.2307/2965726.
- 1063 Sikorska K, Lesaffre E, Groenen PJF, Rivadeneira F, Eilers PHC. 2018. Genome-wide analysis

- 1064 of large-scale longitudinal outcomes using penalization GALLOP algorithm. Sci Rep. 8(1).
- 1065 doi:10.1038/s41598-018-24578-7.
- 1066 Sobel ME. 1982. Asymptotic confidence intervals for indirect effects in structural equation
- 1067 models. Sociol Methodol. 13:290. doi:10.2307/270723.
- 1068 https://www.jstor.org/stable/270723?origin=crossref.
- 1069 Song X, Davidian M, Tsiatis AA. 2002. A semiparametric likelihood approach to joint modeling
- 1070 of longitudinal and time-to-event data. Biometrics. 58(4):742–53. doi:10.1111/j.0006-
- 1071 341x.2002.00742.x. http://www.ncbi.nlm.nih.gov/pubmed/12495128.
- 1072 Sun L, Dimitromanolakis A, Faye LL, Paterson AD, Waggott D, DCCT/EDIC Research Group,
- 1073 Bull SB. 2011. BR-squared: a practical solution to the winner's curse in genome-wide scans.
- 1074 Hum Genet. 129(5):545–52. doi:10.1007/s00439-011-0948-2.
- 1075 http://www.ncbi.nlm.nih.gov/pubmed/21246217.
- 1076 Sweeting MJ, Thompson SG. 2011. Joint modelling of longitudinal and time-to-event data with
- 1077 application to predicting abdominal aortic aneurysm growth and rupture. Biometrical J.
- 1078 53(5):750–763. doi:10.1002/bimj.201100052.
- 1079 Tang AM, Tang NS. 2014. Semiparametric Bayesian inference on skew-normal joint modeling
- 1080 of multivariate longitudinal and survival data. Stat Med. 34(5):824–843. doi:10.1002/sim.6373.
- 1081 Tang NS, Tang AM, Pan DD. 2014. Semiparametric Bayesian joint models of multivariate
- 1082 longitudinal and survival data. Comput Stat Data Anal. 77:113–129.
- 1083 doi:10.1016/j.csda.2014.02.015.

- 1084 The 1000 Genomes Project Consortium. 2015. A global reference for human genetic variation.
- 1085 Nature. 526(7571):68–74. doi:10.1038/nature15393.
- 1086 http://www.ncbi.nlm.nih.gov/pubmed/26432245.
- 1087 The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive
- 1088 treatment of diabetes on the development and progression of long-term complications in insulin-
- 1089 dependent diabetes mellitus. N Engl J Med. 329(14):977–986.
- 1090 doi:10.1056/NEJM199309303291401. [accessed 2019 Aug 15]. www.nejm.org.
- 1091 Therneau TM. 2020. A Package for survival analysis in R. R package version 3.2-7, URL
- 1092 http://CRAN.R-project.org/package=survival. https://cran.r-project.org/package=survival.
- 1093 Therneau TM, Grambsch PM. 2000. Modeling survival data: extending the Cox model. New
- 1094 York, NY: Springer New York (Statistics for Biology and Health). [accessed 2019 Aug 8].
- 1095 https://books.google.ca/books?id=oj0mBQAAQBAJ&printsec=frontcover&dq=therneau+and+gr
- 1096 ambsch&hl=fr&sa=X&ved=0ahUKEwjZ96antfPjAhWXHM0KHbxCCoAQ6AEILDAA#v=one
- 1097 page&q=age1&f=false.
- 1098 Tsiatis AA, Davidian M. 2001. A semiparametric estimator for the proportional hazards model
- 1099 with longitudinal covariates measured with error. Biometrika. 88(2):447–458.
- 1100 doi:10.1093/biomet/88.2.447. https://academic.oup.com/biomet/article-
- 1101 lookup/doi/10.1093/biomet/88.2.447.
- 1102 Tsiatis AA, Davidian M. 2004. Joint modeling of longitudinal and time-to-event data: An
- 1103 overview. Stat Sin. 14(3):809–34.
- 1104 Tsiatis AA, Degruttola V, Wulfsohn MS. 1995. Modeling the relationship of survival to

- 1105 longitudinal data measured with error. Applications to survival and CD4 counts in patients with
- 1106 AIDS. J Am Stat Assoc. 90(429):27–37. doi:10.1080/01621459.1995.10476485.
- 1107 https://about.jstor.org/terms.
- 1108 Wheeler E, Leong A, Liu C-TT, Hivert M-FF, Strawbridge RJ, Podmore C, Li M, Yao J, Sim X,
- 1109 Hong J, et al. 2017. Impact of common genetic determinants of Hemoglobin A1c on type 2
- 1110 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-
- 1111 analysis. PLoS Med. 14(9):e1002383. doi:10.1371/journal.pmed.1002383.
- 1112 http://www.ncbi.nlm.nih.gov/pubmed/28898252.
- 1113 Wu L, Liu W, Yi GY, Huang Y. 2012. Analysis of longitudinal and survival data: joint
- 1114 modeling, inference methods, and issues. J Probab Stat. 2012:1–17. doi:10.1155/2012/640153.
- 1115 http://www.hindawi.com/journals/jps/2012/640153/.
- 1116 Wulfsohn MS, Tsiatis AA. 1997. A joint model for survival and longitudinal data measured with
- 1117 error. Biometrics. 53(1):330. doi:10.2307/2533118.
- 1118 http://www.ncbi.nlm.nih.gov/pubmed/9147598.
- 1119 Xu J, Zeger SL. 2001. Joint analysis of longitudinal data comprising repeated measures and
- 1120 times to events. J R Stat Soc Ser C (Applied Stat. 50(3):375–387. doi:10.1111/1467-9876.00241.
- 1121 https://onlinelibrary.wiley.com/doi/10.1111/1467-9876.00241.
- 1122 Ye Q, Wu L. 2017. Two-step and likelihood methods for joint models of longitudinal and
- 1123 survival data. Commun Stat Simul Comput. 46(8):6019–6033.
- 1124 doi:10.1080/03610918.2016.1188208. [accessed 2019 Jul 12].
- 1125 https://www.tandfonline.com/doi/full/10.1080/03610918.2016.1188208.

- 1126 Ye W, Lin X, Taylor JMG. 2008. Semiparametric modeling of longitudinal measurements and
- 1127 time-to-event data A two-stage regression calibration approach. Biometrics. 64(4):1238–1246.
- 1128 doi:10.1111/j.1541-0420.2007.00983.x.
- 1129 Young AI, Benonisdottir S, Przeworski M, Kong A. 2019. Deconstructing the sources of
- 1130 genotype-phenotype associations in humans. Science. 365(6460):1396–1400.
- 1131 doi:10.1126/science.aax3710. http://science.sciencemag.org/.
- 1132 Yuen HP, Mackinnon A, Hartmann J, Amminger GP, Markulev C, Lavoie S, Schäfer MR, Polari
- 1133 A, Mossaheb N, Schlögelhofer M, et al. 2018. Dynamic prediction of transition to psychosis
- 1134 using joint modelling. Schizophr Res. 202(2018):333–340. doi:10.1016/j.schres.2018.07.002.
- 1135 https://doi.org/10.1016/j.schres.2018.07.002.
- 1136 Zhu H, Ibrahim JG, Chi YY, Tang N. 2012. Bayesian influence measures for joint models for
- 1137 longitudinal and survival data. Biometrics. 68(3):954–964. doi:10.1111/j.1541-
- 1138 0420.2012.01745.x.
- 1139
- 1140

1141 Appendix

1142 Joint likelihood function of the joint model of one longitudinal and one time-to-event trait (L=K=1)

1143 Under the following assumptions (A1-A3),

1144 (A1)
$$\boldsymbol{b}_i \sim N_2(0, \boldsymbol{D})$$
, where $\boldsymbol{b}_i = (b_{i,0}, b_{i,1})^T$ are subject-specific random effects

1145 (A2)
$$\varepsilon_{i,j} \sim N(0, \sigma^2)$$
 and $\varepsilon_{i,j} \perp \varepsilon_{i,s}$ between visit times $t_{i,j} \neq t_{i,s}$, with $j \neq s$, for all $1 \leq 1$

1146 $j \le J$ and $1 \le s \le J$

1147 (A3)
$$\boldsymbol{b}_{i} \perp \boldsymbol{\varepsilon}_{i}$$
, where $\boldsymbol{\varepsilon}_{i} = (\varepsilon_{i,1}, \dots, \varepsilon_{i,j}, \dots, \varepsilon_{i,J})^{T}, \boldsymbol{\varepsilon}_{i} \sim N_{J}(0, \sigma^{2}\boldsymbol{I}_{J})$

Then conditional on the random effects \boldsymbol{b}_i and fixed effects $\boldsymbol{\Omega}$, it is appropriate to assume: the repeated measurements in the longitudinal process are independent (Laird and Ware 1982), in other words that the serial correlation is taken into account; and the longitudinal and time-to-event trait models are independent (Ibrahim et al. 2001). Under these conditional independence assumptions, the joint likelihood function of the joint model parameters $\boldsymbol{\Omega}$ given the observed data is:

1154
$$L(\boldsymbol{\Omega}|\boldsymbol{y}_{i}, T_{i}, \delta_{i}) = \prod_{i=1}^{N} \int f_{1}(\boldsymbol{y}_{i}|\boldsymbol{b}_{i}, \boldsymbol{\Omega}) \times f_{2}(T_{i}, \delta_{i}|\boldsymbol{b}_{i}, \boldsymbol{\Omega}) \times f_{3}(\boldsymbol{b}_{i}|\boldsymbol{\Omega}) d\boldsymbol{b}_{i}$$

1155 where:

1156 •
$$f_1(\mathbf{y}_i | \mathbf{b}_i, \mathbf{\Omega}) = (2\pi\sigma^2)^{-J/2} \prod_{j=1}^J \exp\left(\frac{(y_{i,j} - y_i^*(t_{i,j}))^2}{2\sigma^2}\right)$$

1157 •
$$f_2(T_i, \delta_i \mid \boldsymbol{b_i}, \boldsymbol{\Omega}) = [\lambda_i(T_i \mid \boldsymbol{b_i}, \boldsymbol{\Omega})]^{\delta_i} S_i(T_i \mid \boldsymbol{b_i}, \boldsymbol{\Omega}), \text{ with}$$

1158 •
$$S_i(T_i | \boldsymbol{b}_i, \boldsymbol{\Omega}) = exp\left[-\int_0^{T_i} \lambda_0(s) exp\{\alpha w_i(s) + \gamma_g g_i\} ds\right] \text{ and } w_i(t) = f(y_i^*(t))$$

1159 where $y_i^*(t)$, denotes the l^{th} QT trajectory at time t for $1 \le l \le L$ which depends on the 1160 fixed and random effects $\boldsymbol{\beta}$ and \boldsymbol{b}_i . The survival function depends on the whole QT history

1161 of the true unobserved longitudinal process up to time *t*, noted as $Y_i^*(t) = \{y_i^*(s), 0 \le s \le t\}$

1163 •
$$f_3(\boldsymbol{b}_i|\boldsymbol{\Omega}) = (2\pi)^{-q/2}|\boldsymbol{D}|^{-1/2}exp\left\{-\frac{1}{2}\boldsymbol{b}_i^T\boldsymbol{D}^{-1}\boldsymbol{b}_i\right\}$$
, where q is the dimension of the D

1164 matrix.

t};

1165 The event indicator δ_i is used to distinguish the contribution of the individuals who experience the 1166 event during the observation period from the individuals who are still at risk up to that time point 1167 but do not experience the event. Individuals who experience the event ($\delta_i = 1$) contribute to the 1168 cumulative hazard function and to the hazard function both evaluated at the T_i ; the individuals who 1169 do not experience the event ($\delta_i = 0$) contribute to the hazard function only.

1170 Joint model parameter estimation can be performed by maximization of the full joint likelihood 1171 function directly or by Bayesian computation. Direct maximization of the joint likelihood function 1172 can be performed using the Expectation-Maximization (EM) algorithm, treating the random effects 1173 as missing data (Wulfsohn and Tsiatis 1997). However, integrals with respect of time in the definition of the survival function, as well as the integral with respect to the b_i do not have an 1174 1175 analytical solution; therefore, numerical approaches, such as adaptive Gauss-Hermit quadrature, 1176 need to be used. Implementations of this model using a maximization of the above joint likelihood 1177 function have been proposed in different R packages (see (Furgal et al. 2019) for a review). 1178 However, as the dimension of the random effects increases, the integral over the random effects 1179 becomes computationally burdensome and Bayesian approaches can be employed instead, where 1180 the random effects are also considered model parameters obtained as a posterior sample and thus 1181 the integral over the random effects is no longer required.

1182 Joint model of multiple longitudinal and multiple time-to-event traits

1183 Joint likelihood function

1184 Extending the previous joint model assumptions (A1-A3) to L>1 and K>1, we have

1185 (A1)
$$\boldsymbol{b}_i \sim N_2(0, \boldsymbol{D})$$
, where $\boldsymbol{b}_i = (\boldsymbol{b}_{i,1}, \dots, \boldsymbol{b}_{i,l}, \dots, \boldsymbol{b}_{i,L})^T$ are subject-specific random effects

1186 for all *L* QTs

1187 (A2)
$$\boldsymbol{\varepsilon}_{i,l} \sim N_{J} \left(\mathbf{0}, \sigma_{l}^{2} \boldsymbol{I}_{J} \right)$$
 for all $l^{\text{th}} \text{QT}$ with $1 \le l \le L$

1188 (A3)
$$\boldsymbol{b}_{i,l} \perp \boldsymbol{\varepsilon}_{i,l}$$
 for all l^{th} QT with $1 \le l \le L$, and

1189 (A4) $u_i \perp b_{i,l}$, where u_i is a shared subject-specific frailty for k time-to-event traits.

1190 Then, conditional on the random effects \boldsymbol{b}_i , the frailty u_i , and fixed effects $\boldsymbol{\Omega}$, we further assume: 1191 \boldsymbol{b}_i accounts for association among the *L* longitudinal traits (Shah et al. 1997) and association 1192 between the longitudinal and time-to-event outcomes (Ibrahim et al. 2001); and the frailty term 1193 accounts for residual dependence among the time-to-event traits (Hougaard 1995). Under these 1194 conditional independence assumptions, the joint likelihood function of the joint model parameters 1195 $\boldsymbol{\Omega}$ given the observed data is:

1196
$$L(\boldsymbol{\Omega}|\boldsymbol{y}_{i},\boldsymbol{T}_{i},\boldsymbol{\delta}_{i}) = \prod_{i=1}^{N} \int f_{1}(\boldsymbol{y}_{i}|\boldsymbol{b}_{i},\boldsymbol{\Omega}) \times f_{2}(\boldsymbol{T}_{i},\boldsymbol{\delta}_{i}|\boldsymbol{b}_{i},u_{i},\boldsymbol{\Omega}) \times f_{3}(\boldsymbol{b}_{i}|\boldsymbol{\Omega}) \times f_{4}(u_{i}|\boldsymbol{\Omega}) du_{i}db_{i}$$

1197 where:

1198 •
$$(T_i, \delta_i) = ((T_{i,1}, \delta_{i,1}), ..., (T_{i,k}, \delta_{i,k}), ..., (T_{i,K}, \delta_{i,K}))^T$$
 is defined as the vector of *K* stacked
1199 time-to-event outcomes for individual *i*,

1200 •
$$f_1(\mathbf{y}_i | \mathbf{b}_i, \mathbf{\Omega}) = \prod_{l=1}^{L} f(\mathbf{y}_{i,l} | \mathbf{b}_{i,l}, \mathbf{\Omega}_l) \text{ with } f(\mathbf{y}_{i,l} | \mathbf{b}_{i,l}, \mathbf{\Omega}_l) =$$

1201
$$(2\pi\sigma_l^2)^{-\frac{J}{2}}exp\left[-\frac{1}{2\sigma_l^2}\prod_{j=1}^J(y_{i,j,l}-y_{i,l}^*(t_{i,j}))^2\right]$$

1202 •
$$f_2(\boldsymbol{T}_i, \boldsymbol{\delta}_i \mid \boldsymbol{b}_i, u_i, \boldsymbol{\Omega}) = \prod_{k=1}^{K} [\lambda_{i,k} (T_{i,k} \mid \boldsymbol{b}_i, u_i, \boldsymbol{\Omega})]^{\delta_{i,k}} S_{i,k} (T_{i,k} \mid \boldsymbol{b}_i, u_i, \boldsymbol{\Omega}) , \text{ with}$$

1203
$$S_{i,k}(T_{i,k} | \boldsymbol{b}_i, u_i, \boldsymbol{\Omega}) = exp \left[-\int_0^{T_{i,k}} \lambda_{0,k}(s) exp \{ \sum_{l=1}^L \alpha_{l,k} w_{i,l,k}(s) \} + \gamma_{g,k} g_i + u_i \} \right]$$

1204
$$w_{i,l,k}(s) = f_{l,k}\left(y_{i,l}^*(t)\right)$$
, where $y_{i,l}^*(t)$, denotes the l^{th} QT trajectory at time t for $1 \le l \le$
1205 L which depends on the fixed and random effects $\boldsymbol{\beta}_l$ and $\boldsymbol{b}_{i,l}$.

1206 •
$$f_3(\boldsymbol{b}_i|\boldsymbol{\Omega}) = (2\pi)^{-q/2} |\boldsymbol{D}|^{-\frac{1}{2}} exp\left[-\frac{1}{2}\boldsymbol{b}_i^T \boldsymbol{D}^{-1} \boldsymbol{b}_i\right]$$
, where q is the dimension of the **D** matrix

1207 •
$$f_4(u_i|\boldsymbol{\Omega}) = \frac{u_i^{a-1}\exp(-u_i/b)}{\Gamma(a)b^a}$$
, i.e. we assume $u_i \sim \text{Gamma}(a, b)$ with $u_i > 0$, a correspondence

1208 to the shape parameter and *b* to the scale parameter, and *a*, *b*>0. $\Gamma(a)$ is the gamma function 1209 evaluated at *a*.

1210 We are not aware of any existing implementations of full likelihood maximization of the extended 1211 model in the literature. Calculation of the full likelihood requires multivariate integration with 1212 respect to the random effects distribution, which can lead to demanding computation. When the 1213 random effect vector \boldsymbol{b}_{i} has a small dimension, say less than 3, the integral can be evaluated via 1214 Gaussian quadrature which approximates the integral by a weighted sum of the target function 1215 evaluated at pre-specified sample points. However, when the dimension is larger, it is demanding 1216 to calculate the integrals with satisfactory approximation accuracy. Although a full likelihood 1217 specification enables rigorous study of asymptotic properties, its large sample approximation may 1218 not be accurate when sample size is small. In comparison, the Bayesian paradigm does not require 1219 asymptotic approximations, but the design of an efficient sampling algorithm to study the posterior 1220 distribution is challenging. Because of these limitations, we implement a two-stage approach to

ds and

estimation of fixed effect parameters in the extended multi-trait model that is reasonable for the GWAS application of interest; in particular the longitudinal measurements in DCCT are taken according to a pre-specified schedule and are not terminated by the observation of diabetes complications, loss to follow-up and mortality are minimal, censoring is administrative, and each individual has a dense and nearly complete set of measurements.

1226 Likelihood functions under the two-stage approximation

1227 Let $\boldsymbol{\Omega}_{Long}$ and $\boldsymbol{\Omega}_{Surv}$ be the vectors containing all fixed parameters from the longitudinal and 1228 time-to-event sub-models respectively.

1229 *Stage 1*: Multivariate mixed model

1230
$$L(\boldsymbol{\Omega}_{Long}|\boldsymbol{y}_{i}) = \prod_{i=1}^{N} \int_{\boldsymbol{b}_{i}} f_{1}(\boldsymbol{y}_{i}|\boldsymbol{b}_{i}, \boldsymbol{\Omega}_{Long}) \times f_{3}(\boldsymbol{b}_{i}|\boldsymbol{\Omega}_{Long}) d\boldsymbol{b}_{i}$$

1231 Where:

1232 •
$$f_1(\mathbf{y}_i | \mathbf{b}_i, \mathbf{\Omega}_{Long}) = \prod_{l=1}^{L} f(\mathbf{y}_{i,l} | \mathbf{b}_i, \mathbf{\Omega}_{Long})$$
 with $f(\mathbf{y}_{i,l} | \mathbf{b}_i, \mathbf{\Omega}_{Long}) =$

1233
$$(2\pi\sigma_l^2)^{-\frac{J}{2}}exp\left[-\frac{1}{2\sigma_l^2}\prod_{j=1}^J(y_{i,j,l}-y_{i,l}^*(t_{i,j}))^2\right]$$

1234 •
$$f_3(\boldsymbol{b}_i | \boldsymbol{\Omega}_{Long}) = (2\pi)^{-q/2} |\boldsymbol{D}|^{-\frac{1}{2}} exp\left[-\frac{1}{2} \boldsymbol{b}_i^T \boldsymbol{D}^{-1} \boldsymbol{b}_i\right]$$
 where q is the dimension of the \boldsymbol{D}

1235 matrix.

The fixed-effect and random-effect parameters are estimated jointly for all longitudinal traits using
all available repeated measurements, without using the time-to-event information. Then fitted
trajectory values are obtained by plugging the parameter estimates into:

1239
$$\mathbf{y}_{i,l}^*(t) = \mathbf{X}_i(t)\boldsymbol{\beta}_l + \mathbf{Z}_i(t)\boldsymbol{b}_{i,l}$$

1240 where
$$X_i(t) = (1, t, g_i)$$
 and $Z_i(t) = (1, t)$

1241 *Stage 2*: Multivariate Cox PH model adjusted for fitted trajectory values for the vector of L
1242 longitudinal outcomes

1243
$$L(\boldsymbol{\Omega}_{\boldsymbol{Surv}}|\boldsymbol{T}_{i},\boldsymbol{\delta}_{i},\widehat{\boldsymbol{w}_{i}(T_{i})}) = \prod_{i=1}^{N} \int_{u_{i}} f_{2}(\boldsymbol{T}_{i},\boldsymbol{\delta}_{i} | u_{i},\widehat{\boldsymbol{w}_{i}(T_{i})},\boldsymbol{\Omega}_{\boldsymbol{Surv}}) \times f_{4}(u_{i}|\boldsymbol{\Omega}_{\boldsymbol{Surv}}) \times du_{i}$$

1244 With:

1245
$$f_2(\boldsymbol{T}_i, \boldsymbol{\delta}_i \mid u_i, \widehat{\boldsymbol{w}_i}(\boldsymbol{T}_i), \boldsymbol{\Omega}_{Surv}) =$$
1246
$$\prod_{k=1}^{K} [\lambda_{i,k}(T_{i,k} \mid u_i, \widehat{\boldsymbol{w}_{i,k}}(\boldsymbol{T}_{i,k}), \boldsymbol{\Omega}_{Surv})]^{\delta_{i,k}} S_{i,k}(T_{i,k} \mid u_i, \widehat{\boldsymbol{w}_{i,k}}(\boldsymbol{T}_{i,k}), \boldsymbol{\Omega}_{Surv}), \text{ and}$$

1247
$$S_{i,k}(T_{i,k} | u_i, \widehat{w_{i,k}(T_{i,k})}, \Omega_{Surv}) = exp \left[-\int_0^{T_{i,k}} \lambda_{i,0}(s) exp \{ \sum_{l=1}^L \alpha_{l,k} \ \widehat{w_{i,l,k}(s)} + \gamma_{g,k} \ g_i + u_i \} ds \right],$$

1248 where $\widehat{w_{i,l,k}(s)}$ is obtained by plugging fitted trajectory values into $w_{i,l,k}(t) = f_{l,k}\left(y_{i,l}^*(t)\right)$.

Unlike the *joint likelihood function*, where the shared random effects b_i account for the 1249 1250 dependencies between the longitudinal and the time-to-event traits, the two-stage approach 1251 accounts for the dependencies between the longitudinal and time-to-event traits via the fitted 1252 values of the longitudinal trajectories. This approximation can produce biased estimates and/or 1253 underestimated standard errors for longitudinal and survival model parameters, when there is non-1254 random censoring of the longitudinal trait values due to the occurrence of an event or from 1255 informative dropout (Ye et al. 2008; Albert and Shih 2010), and because of propagation errors of 1256 Stage 1 parameter estimates into Stage 2 (Wulfsohn and Tsiatis 1997). Under longitudinal model

1257 mis-specification and estimation bias, the conditional independence assumption can fail, 1258 undermining the accurate of trajectory estimates. Because the time-to-event processes are related 1259 to length of follow-up, informative missingness/dropouts can lead to differential follow-up 1260 between subjects with and without an event, and thus the random effects b_i can depend on the 1261 event times (e.g. patients who have an event early are more likely to have positive random slopes). 1262 However, as we show in the simulation studies, in absence of model mis-specification and 1263 informative dropouts/missingness, this approach has low bias and is computationally feasible for 1264 genetic association studies.

Fig. 1. Directed acyclic graph (DAG) illustrating the joint model parameters to characterize the direct SNP effect on the time-to-event trait and the indirect SNP effect via the intermediate longitudinal QT associated with the time-to-event trait. Figure adapted from (Ibrahim et al. 2010) which proposed a general joint model formulation for one longitudinal QT and one time-to-event trait to address questions specific to testing for treatment effects in randomized-controlled clinical trials.





Fig. 2. Proposed joint modelling approach for characterization of complex genetic architecture of multiple disease progression



accounts for shared and/or trait-specific covariates

Fig. 3. Realistic DCCT-data-based causal genetic scenario

We generated R=1000 replicates of N=667 DCCT individuals with M=5 causal variants and K=2 time-to-event traits simulated under this causal genetic scenario, and R=1000 replicates of M=5 SNPs (with same MAF as the causal ones) simulated under a *global null* genetic scenario where none of the SNPs is associated with any traits. The effects of gender on SBP, and of T1D duration at baseline on both time-to-T1DC traits are not represented in this figure, but are included in the data generating model, see File S2 (sections 2 and 3) for details.





Fig. 4. Illustration of the procedure developed for DCCT-based simulation study under the scenario from Fig. 3



For each individual *i*, with { t_i , $y_{i,1}$, $y_{i,2}$ } observed in DCCT, the algorithm simulate: latent longitudinal QT values for $U(y_{i,u})$, genetic data at *M* causal SNPs (with *p*, the specified vector of MAFs) and time-to-T1DC data ($T_{i,k}$, $\delta_{i,k}$) for *K*=2 time-to-T1DC traits. The genetic data are simulated under Hardy-Weinberg and linkage equilibrium assumptions. SNPs with indirect effects are simulated from a multinomial distribution with calculated conditional genotype probabilities for individual *i* ($\pi_{g_i=0}, \pi_{g_i=1}, \pi_{g_i=2}$) based on $y_{i,l}$. Each $y_{i,l}$ is assumed to follow a multivariate normal distribution with $X_{i,l}$ and $Z_{i,l}$ the specified fixed and random effect design matrices in longitudinal trait models and $\Omega_l = \{\beta_l, D_l, \sigma_l^2\}$ the vector of specified parameter values for each *l*th QT. SNPs with direct effects are simulated from the population probabilities, that depend only on the MAF. The specified hazard function for each k^{th} time-to-event trait depends on the effects of the longitudinal QT trajectories and on the SNPs with direct effects in $\eta_{i,k}$, with $\eta_{i,1} = \gamma_{g,1} SNP2_i + \alpha_{1,2}y_{i,1}^*(t)$ for DR and $\eta_{i,2} = \gamma_g SNP4_i + \gamma'_g SNP5_i + \alpha_{1,2}y_{i,1}^*(t) + \alpha_{2,2}y_{i,2}^*(t)$ for DN, as well as the effect of the shared latent QT trajectory $y_{i,u}^*(t)$ used to induce some dependencies between the time-to-event traits. We define Γ_k as the vectors of specified parameter values for each k^{th} time-to-event trait. The uncensored event time $T_{i,k}^*$, is simulated by calculating the inverse of the cumulative specified hazard function using the Brent univariate root-finding method (Brent 2013; Crowther and Lambert 2013). To simplify the exposition of the simulation procedure, we ignore the effects of the sex on SBP and of the T1D duration on both T1DC traits, but they were included in the data generating model, see File S2 for details. Parameters for the causal genetic scenario are shown in Fig. 3 and File S2 (sect

Fig. 5. Classification of direct and/or indirect SNP associations in the DCCT Genetics Study data.

(A) Scatter plots of the *P*-values (-log10) for tests of $\beta_{g,l}$ (H0: $\beta_{g,l} = 0$ vs H1 $\beta_{g,l} \neq 0$) on the *X* axis and $\gamma_{g,k}$ (H0: $\gamma_{g,k} = 0$ vs H1: $\gamma_{g,k} \neq 0$) on the *Y* axis for HbA1c/DR, HbA1c/DN and SBP/DN trait pairs. Significance levels $P^* = 1.7 \times 10^{-4}$ and $P^* = 0.05$ are indicated by red and grey horizontal and vertical dashed lines. (**B**) and (**C**) represent association results for rs10810632 and rs1358030 detected as indirect associations at $P^* = 1.7 \times 10^{-4}$. Left panels present results from separate analysis of each trait (*ie*. longitudinal model for each QT and Cox PH time-to-event model without adjusting for the longitudinal traits) as used in naïve discovery GWAS; and right panels show results from the joint model with bootstrap 95% confidence intervals for the direct and indirect SNP effects. Results are presented using time-weighted cumulative HbA1c effects on T1DC traits.





Fig. 6. Change in classification results for rs10810632 with HbA1c/DR to increasing sample size (A) and to the Winner's curse bias for the SNP effect on HbA1c (B) investigated using parametric resampling.



We used parametric resampling (File S3, section 6) to draw datasets with sample size up to five times the DCCT sample size of N=516, and then extrapolated the classification results beyond N=2580. The X axes of (**A**) and (**B**), show the *P*-values (-log10) for the test of rs10810632 effect on HbA1c (H0: $\beta_{g,1} = 0$ vs H1 $\beta_{g,1} \neq 0$)), while the Y axes show the *P*-values (-log10) for the test of rs10810632 effect on DR (H0: $\gamma_{g,1} = 0$ vs H1: $\gamma_{g,1} \neq 0$) for the sample sizes investigated (shown by different colors). We fitted a regression line on each plot to project the trend of the classification beyond N=2580 individuals. These plots illustrate the corresponding shift in classification of rs10810632 association with DR as indirect via HbA1c towards classification as both indirect and direct association. Complete results with HbA1c/DN are shown in File S3 (section 6).

| | | SNP association with the longitudinal risk factor <i>l</i> | | | | | |
|--------------------------|---------------------------------------|---|---|--|--|--|--|
| | | $P_{\beta_{g,l}} \le P_{\beta_g}^*$ | $P_{\beta_{g,l}} > P_{\beta_g}^*$ | | | | |
| SNP association with the | $P_{\gamma_{g,k}} \le P_{\gamma_g}^*$ | Direct & Indirect $\beta_{a,l} \neq 0$ AND $\gamma_{a,k} \neq 0$ | Direct $\beta_{a,l} = 0 \text{ AND } \gamma_{a,k} \neq 0$ | | | | |
| time-to-event trait k | $P_{\gamma_{g,k}} > P_{\gamma_g}^*$ | Indirect $\beta_{g,l} \neq 0 \text{ AND } \gamma_{g,k} = 0$ | Not Direct & Not Indirect $\beta_{q,l} = 0$ AND $\gamma_{q,k} = 0$ | | | | |

 $P_{\beta_{g,l}}$ and $P_{\gamma_{g,k}}$ are *P*-values from Wald tests (1*df*) for each of SNP effects $\beta_{g,l}$ and $\gamma_{g,k}$. For the former, we test H0: $\beta_{g,l} = 0$ vs H1: $\beta_{g,l} \neq 0$. For the latter, H0: $\gamma_{g,k} = 0$ vs H1: $\gamma_{g,k} \neq 0$. $P_{\beta_g}^*$ and $P_{\gamma_g}^*$ are the corresponding classification thresholds (see Materials and Methods for details). For example, if the H0: $\beta_{g,l} = 0$ is rejected and H0: $\gamma_{g,k} = 0$ is rejected by the corresponding test statistics, then the SNP is classified as being both indirectly and directly associated with the time-to-event trait *k*. The classification procedure is based on the two separate test statistics and does not require a joint test statistic of the overall SNP effect; it thus partitions the two-dimensional parameter space into four mutually exclusive quadrants. In the simulations and application, we use $P^* = P_{\beta_g}^* = P_{\gamma_g}^*$, although different thresholds can be specified for $P_{\beta_g}^*$ and $P_{\gamma_g}^*$.

<u>Table 1</u>. Procedure to classify a SNP as having an association with a time-to-event trait *k*, indirectly through an associated longitudinal risk factor *l* and/or directly with trait *k*, based on hypothesis tests of SNP effects $\beta_{g,l}$ and $\gamma_{g,k}$.

| | | | lobal null | | / | Genetic alternative at $P^*=5\%$ | | | | | |
|-------------------|-------------------------------------|--------------------------|-----------------|-------------------|---------------------|----------------------------------|--------------------------|------------------------------|-------------------------------|--|--|
| SNPs ¹ | Analysis Models | HbA1c | SBP | $\frac{dl I}{DR}$ | DN | HbA1c | SBP | DR | DN | | |
| | | $\beta_{g,1}=0$ | $\beta_{g,2}=0$ | $\gamma_{g,1}=0$ | $\gamma_{g,2}=0$ | $\beta_{g,1}=0.7$ | $\beta_{g,2}=0$ | $\gamma_{g,1}=0$ | $\gamma_{g,2}=0$ | | |
| | JM-cmp | 5.2 | 5.8 | 4.4 | 4.8 | $\frac{p_{g,1}=0.7}{100}$ | <u> </u> | 4.1 | 5.4 | | |
| | JM-mis | 5.2 | 5.8 | 3.6 | 4.9 | 100 | 5.1 | 4.2 | 4.6 | | |
| SNP1 | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | 5.2 | 5.8 | 3.8 | 1.2 | 100 | 5.1 | 4.7 | 1.0 | | |
| (MAF= | JM-sep(l=1,2; k=2) | 5.2 | 5.8 | 010 | 5.2 | 100 | 5.1 | , | 4.6 | | |
| 30%) | JM-sep(l=1; k=1) | 5.6 | | 4.0 | | 100 | | 4.6 | | | |
| | JM-sep(<i>l</i> =1; <i>k</i> =2) | 5.6 | | | 4.6 | 100 | | | 5.7 | | |
| | JM-sep(<i>l</i> =2; <i>k</i> =2) | | 5.9 | | 4.6 | • | 5.2 | | 11.2 | | |
| | | $\beta_{\mathrm{g},1}=0$ | $\beta_{g,2}=0$ | $\gamma_{g,1}=0$ | $\gamma_{g,2}=0$ | $\beta_{\mathrm{g},1}=0$ | $\beta_{g,2}=0$ | <i>γ</i> _{g,1} =0.8 | $\gamma_{g,2}=0$ | | |
| | JM-cmp | 5.5 | 6.0 | 5.8 | 3.9 | 6.6 | 5.4 | 100 | 3.9 | | |
| SNP2 | JM-mis | 5.5 | 6.0 | 4.5 | 3.8 | 6.6 | 5.4 | 100 | 4.6 | | |
| (MAF= | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | 5.5 | 6.0 | 5.0 | | 6.6 | 5.4 | 100 | | | |
| (101A1) = 10%) | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | 5.5 | 6.0 | | 4.4 | 6.6 | 5.4 | • | 5.2 | | |
| 10/0) | JM-sep(<i>l</i> =1; <i>k</i> =1) | 5.0 | • | 5.0 | | 6.1 | • | 100 | • | | |
| | JM-sep(<i>l</i> =1; <i>k</i> =2) | 5.0 | | | 5.1 | 6.1 | • | • | 4.6 | | |
| | JM-sep(<i>l</i> =2; <i>k</i> =2) | | 6.7 | • | 4.9 | | 5.2 | • | 4.7 | | |
| | | $\beta_{\rm g,1}=0$ | $\beta_{g,2}=0$ | $\gamma_{g,1}=0$ | $\gamma_{g,2}=0$ | $\beta_{\mathrm{g},1}=0$ | $\beta_{\mathrm{g},2}=0$ | $\gamma_{g,1}=0$ | $\gamma_{g,2}=0$ | | |
| | JM-cmp | 4.0 | 6.7 | 4.3 | 4.5 | 4.5 | 4.6 | 4.7 | 3.8 | | |
| SNP3 ¹ | JM-mis | 4.0 | 6.7 | 4.6 | 3.9 | 4.5 | 4.6 | 89.9 | 58.4 | | |
| (MAF= | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | 4.0 | 6.7 | 4.7 | | 4.5 | 4.6 | 89.7 | • | | |
| (101A1 - 40%) | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | 4.0 | 6.7 | • | 4.4 | 4.5 | 4.6 | | 57.7 | | |
| +070) | JM-sep(<i>l</i> =1; <i>k</i> =1) | 4.1 | | 4.6 | | 4.8 | | 89.7 | • | | |
| | JM-sep(<i>l</i> =1; <i>k</i> =2) | 4.1 | | | 4.6 | 4.8 | | | 33.0 | | |
| | JM-sep(<i>l</i> =2; <i>k</i> =2) | • | 6.5 | • | 4.8 | | 4.4 | • | 56.4 | | |
| | | $\beta_{\mathrm{g},1}=0$ | $\beta_{g,2}=0$ | $\gamma_{g,1}=0$ | $\gamma_{g,2}=0$ | $\beta_{\mathrm{g},1}=0$ | $\beta_{\mathrm{g},2}=0$ | $\gamma_{g,1}=0$ | $\gamma_{g,2} = 0.7$ | | |
| | JM-cmp | 4.8 | 6.3 | 3.9 | 4.9 | 5.4 | 4.8 | 6.0 | 100 | | |
| SNP4 | JM-mis | 4.8 | 6.3 | 4.9 | 4.7 | 5.4 | 4.8 | 5.4 | 100 | | |
| (MAF= | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | 4.8 | 6.3 | 4.9 | | 5.4 | 4.8 | 5.1 | • | | |
| (1011 ff = 30%) | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | 4.8 | 6.3 | • | 5.1 | 5.4 | 4.8 | | 99.9 | | |
| 2070) | JM-sep(<i>l</i> =1; <i>k</i> =1) | 5.0 | | 4.6 | | 6.1 | • | 5.1 | • | | |
| | JM-sep(<i>l</i> =1; <i>k</i> =2) | 5.0 | | • | 5.0 | 6.1 | • | • | 93.9 | | |
| | JM-sep(<i>l</i> =2; <i>k</i> =2) | • | 5.6 | • | 4.8 | | 4.8 | | 99.9 | | |
| | | $\beta_{\rm g,1}=0$ | $\beta_{g,2}=0$ | $\gamma_{g,1}=0$ | γ _{g,2} =0 | $\beta_{\mathrm{g},1}=0$ | $\beta_{\rm g,2}=7$ | $\gamma_{g,1}=0$ | γ _{g,2} = 0.4 | | |
| | JM-cmp | 5.0 | 5.5 | 4.7 | 5.6 | 2.8 | 100 | 5.5 | 66.4 | | |
| SNP5 | JM-mis | 5.0 | 5.5 | 4.6 | 4.5 | 2.8 | 100 | 4.6 | 64.5 | | |
| (MAF= | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | 5.0 | 5.5 | 5.2 | | 2.8 | 100 | 4.8 | • | | |
| 20%) | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | 5.0 | 5.5 | • | 5.0 | 2.8 | 100 | • | 63.2 | | |
| | JM-sep(<i>l</i> =1; <i>k</i> =1) | 5.1 | | 5.3 | | 2.8 | • | 4.6 | • | | |
| | JM-sep(<i>l</i> =1; <i>k</i> =2) | 5.1 | | • | 4.9 | 2.8 | • | | 100 | | |
| | JM-sep(<i>l</i> =2; <i>k</i> =2) | • | 5.6 | • | 5.4 | | 100 | | 64.9 | | |

¹Except for JM-cmp, none of the analyses account for indirect genetic pathways via the longitudinal risk factor *U*. This translates into elevated T1E in the direct genetic effects $\gamma_{a,k}$ for both time-to-T1DC traits.

<u>Table 2</u>. Empirical type-I error and power (%) for SNP hypothesis tests of each of $\beta_{g,l}$ and $\gamma_{g,k}$ based on the complete joint model and compared models, assessed using *R*=1000 replicates of *N*=667 DCCT subjects, with SNPs simulated under *global genetic null* and *genetic alternative* simulation scenarios.

Values are computed for each SNP and each genetic association parameter as the proportion of replicates that reject the null hypothesis at significance threshold $P^*=0.05$. Results at other significance levels P^* , and also for CM-obs, are shown in File S2, under the global null scenario at $P^* \leq 0.01$ (section 7), and under the alternative genetic scenario at $P^* \leq 10^{-5}$ (section 8).

Table 3. Classification frequencies for SNP1 association with each of the QT/time-to-event trait pairs based on the complete joint model and compared models at significance threshold $P^*=0.05$, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

| SNP | Trait pairs | Analysis Model | Mean | Bias ¹ | | an Bootstra | | Classification frequencies (%) Expected ³ (above) vs Empirical Values ⁴ | | | | |
|---------------|--|-------------------------------------|-----------------------|---------------------|------------------------------------|-----------------------------------|------------------------|--|--------|----------------------|------------------------------|--|
| | | | β _{g,1} =0.7 | $\gamma_{g,1}=0$ | $\widehat{\sigma_{\!\beta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,1}}}$ | $\widehat{\rho_{1,1}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | $III_{h} = \frac{1}{2} $ | | • | • - | . 9,1 | <u>ē</u> . | | 95.0 | 0 | 5.0 | 0 | |
| | HbA1c(<i>l</i> =1)/ DR(<i>k</i> =1) | JM-cmp | | 0.002 | | 0.009 | -0.003 | 95.9 | 0 | 4.1 | 0 | |
| | DR(k-1) | JM-mis | -0.051 | < 0.001 | 0.006 | 0.010 | -0.002 | 95.8 | 0 | 4.2 | 0 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | | < 0.001 | | 0.008 | -0.002 | 95.3 | 0 | 4.7 | 0 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =1) | -0.047 | < 0.001 | 0.006 | 0.008 | -0.002 | 95.4 | 0 | 4.6 | 0 | |
| | | CM-obs | -0.051 | 0.032 | 0.006 | 0.009 | 0.041 | 93.6 | 0 | 6.4 | 0 | |
| | HbA1c(<i>l</i> =1)/ DN(<i>k</i> =2) | | β _{g,1} =0.7 | γ _{g,2} =0 | $\widehat{\sigma_{\beta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{1,2}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | | | | | F 1,2 | 95.0 | 0 | 5.0 | 0 | |
| SNP1 (MAF= | | JM-cmp | -0.051 | -0.011 | 0.006 | 0.021 | -0.012 | 94.6 | 0 | 5.4 | 0 | |
| (MA1 - 30%) | | JM-mis | | -0.014 | | 0.024 | -0.010 | 95.4 | 0 | 4.6 | 0 | |
| 30%) | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | -0.011 | | 0.021 | -0.009 | 95.4 | 0 | 4.6 | 0 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =2) | -0.047 | -0.004 | 0.006 | 0.019 | -0.005 | 94.3 | 0 | 5.7 | 0 | |
| | | CM-obs | -0.051 | 0.018 | 0.006 | 0.016 | 0.018 | 94.3 | 0 | 5.7 | 0 | |
| | | | $\beta_{g,2}=0$ | γ _{g,2} =0 | $\widehat{\sigma_{\beta_{g,2}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{2,2}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | | | . 9,- | . 9,- | , | 4.75 | 4.75 | 0.25 | 90.25 | |
| | SBP(<i>l</i> =2)/ | JM-cmp | | -0.011 | | 0.021 | -0.021 | 5.0 | 5.3 | 0.1 | 89.6 | |
| | DN(<i>k</i> =2) | JM-mis | -0.053 | -0.014 | 0.233 | 0.024 | -0.012 | 5.1 | 4.6 | 0 | 90.3 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | -0.011 | | 0.021 | -0.009 | 5.1 | 4.6 | 0 | 90.3 | |
| | | JM-sep(<i>l</i> =2; <i>k</i> =2) | -0.053 | 0.095 | 0.232 | 0.019 | -0.007 | 4.3 | 10.3 | 0.9 | 84.5 | |
| | | CM-obs | -0.053 | 0.018 | 0.233 | 0.016 | 0.313 | 4.5 | 5.1 | 0.6 | 89.8 | |

¹Mean Bias in the SNP1 effects, $\hat{\beta_{g,l}}$ and $\hat{\gamma_{g,k}}$, estimated by each of the analysis models.

²Mean Bootstrap SE's, $\sigma_{\beta_{a,l}}$ and $\sigma_{\gamma_{a,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and mean correlation $\rho_{l,k}$ over the *R*=1000 replicates.

³*Expected* classification frequencies (%) for each category of association calculated as the probability to classify SNP1 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, under the assumption that $\widehat{Z}_{g} = (\widehat{Z_{\beta_{g,l}}}, \widehat{Z_{\gamma_{g,k}}})^{T}$, constructed from the SNP effect estimates ($\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$) and their bootstrap standard errors ($\widehat{\sigma_{\beta_{g,l}}}$ and $\widehat{\sigma_{\gamma_{g,k}}}$) as $\widehat{Z_{\beta_{g,l}}} = \widehat{\beta_{g,l}}/\sigma_{\widehat{\beta_{g,l}}}$ and $\widehat{Z_{\gamma_{g,k}}} = \widehat{\gamma_{g,k}}/\sigma_{\widehat{\gamma_{g,k}}}$ from JM-cmp, asymptotically follows a bivariate normal distribution, that is $\widehat{Z}_{g} \sim N_2(E[\mathbf{Z}_g], \mathbf{H})$, where $E[\mathbf{Z}_g]$ is the vector of expectations, and $\mathbf{H} = \begin{pmatrix} 1 & \rho_{l,k} \\ \rho_{l,k} & 1 \end{pmatrix}$ with $\rho_{l,k} = Cor(Z_{\beta_{g,l}}, Z_{\gamma_{g,k}}) = \sigma_{\beta_{g,l}\gamma_{g,k}}/(\sigma_{\beta_{g,l}} \times \sigma_{\gamma_{g,k}})$ and $\sigma_{\beta_{g,l}\gamma_{g,k}}$, the covariance between $\beta_{g,l}$ and $\gamma_{g,k}$ (See File S2, section 9 for details). ⁴Empirical classification frequencies (shown as a percentage, %) for each SNP association under the *alternative* genetic simulation for $\beta_{g,l}$ and $\gamma_{g,k}$ hypothesis tests using the procedure described in Table 1 at $P^* = P_{\beta}^* = P_{\gamma}^* = 0.05$. The results for the correct classification category under the *alternative genetic* simulation scenario from Fig. 3 are shown in bold. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11)

<u>**Table 4.**</u> Classification frequencies for SNP2 association with each QT/time-to-event trait pairs based on the complete joint model and compared models at significance threshold $P^*=0.05$, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

| SNP | Trait pairs | Analysis Model | Mean | Bias ¹ | | Bootstraj Correlat | | Classification frequencies ³ (%) Expected (above) vs Empirical Values | | | | |
|-----------|--|-------------------------------------|-----------------|-----------------------|------------------------------------|-----------------------------------|------------------------|---|--------|----------------------|------------------------------|--|
| | | | $\beta_{g,1}=0$ | γ _{g,1} =0.8 | $\widehat{\sigma_{\beta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,1}}}$ | $\widehat{\rho_{1,1}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | - | | . 9,1 | | | 0 | 95.0 | 5.0 | 0 | |
| | HbA1c(<i>l</i> =1)/ | JM-cmp | | 0.003 | | 0.015 | -0.005 | 0 | 93.4 | 6.6 | 0 | |
| | DR(<i>k</i> =1) | JM-mis | -0.003 | -0.023 | 0.014 | 0.019 | -0.006 | 0 | 93.4 | 6.6 | 0 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | | -0.099 | | 0.015 | -0.007 | 0 | 93.4 | 6.6 | 0 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =1) | -0.003 | -0.099 | 0.014 | 0.015 | -0.006 | 0 | 93.9 | 6.1 | 0 | |
| | | CM-obs | -0.003 | -0.077 | 0.014 | 0.017 | 0.038 | 0 | 93.4 | 6.6 | 0 | |
| | | | $\beta_{g,1}=0$ | γ _{g,2} =0 | $\widehat{\sigma_{\!\beta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{1,2}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | HbA1c(<i>l</i> =1)/ DN(<i>k</i> =2) | | | | | | | 4.75 | 4.75 | 0.25 | 90.25 | |
| SNP2 | | JM-cmp | -0.003 | < 0.001 | | 0.043 | -0.010 | 6.4 | 3.7 | 0.2 | 89.7 | |
| (MAF=10%) | | JM-mis | | -0.003 | 0.014 | 0.048 | -0.011 | 6.3 | 4.3 | 0.3 | 89.1 | |
| (| | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | 0.002 | | 0.042 | -0.011 | 6.2 | 4.8 | 0.4 | 88.6 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =2) | -0.003 | -0.006 | 0.011 | 0.038 | 0.011 | 6.1 | 4.6 | 0 | 89.3 | |
| | | CM-obs | -0.003 | -0.004 | 0.014 | 0.034 | 0.023 | 6.6 | 4.5 | 0 | 88.9 | |
| | | | $\beta_{g,2}=0$ | γ _{g,2} =0 | $\widehat{\sigma_{\beta_{g,2}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{2,2}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | | | . 9,- | . 9,- | | 4.75 | 4.75 | 0.25 | 90.25 | |
| | SBP(<i>l</i> =2)/ | JM-cmp | | < 0.001 | | 0.043 | -0.018 | 5.4 | 3.9 | 0 | 90.7 | |
| | DN(k=2) | JM-mis | -0.004 | -0.003 | 0.513 | 0.048 | -0.012 | 5.4 | 4.6 | 0 | 90.0 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | 0.002 | | 0.042 | -0.008 | 5.3 | 5.1 | 0.1 | 89.5 | |
| | | JM-sep(<i>l</i> =2; <i>k</i> =2) | -0.004 | 0.001 | 0.512 | 0.042 | -0.005 | 5.0 | 4.5 | 0.2 | 90.3 | |
| | | CM-obs | -0.004 | -0.004 | 0.513 | 0.034 | 0.330 | 5.0 | 4.1 | 0.4 | 90.5 | |

¹Mean Bias in the SNP2 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

²Mean Bootstrap SE's, $\sigma_{\beta_{g,l}}$ and $\sigma_{\gamma_{g,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the *R*=1000 replicates.

³*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP2 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

<u>**Table 5.**</u> Classification frequencies for SNP4 association with each pair of QT/time-to-event traits based on the complete joint model and compared models at significance threshold $P^*=0.05$, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

| SNP | Trait pairs | Analysis Model | Mean | Bias ¹ | | Bootstrap S Correlation | | | Classification frequencies ³ (%) Expected (above) vs Empirical Values | | | | | |
|---------------|----------------------|-------------------------------------|-----------------|--------------------------|----------------------------------|-----------------------------------|------------------------|----------|---|----------------------|------------------------------|--|--|--|
| | | | $\beta_{g,1}=0$ | γ _{g,1} =0 | $\widehat{\sigma_{eta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,1}}}$ | $\widehat{\rho_{1,1}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | | | |
| | | | | | 0, | 3,- |)_ | 4.75 | 4.75 | 0.25 | 90.25 | | | |
| | HbA1c(<i>l</i> =1)/ | JM-cmp | | -0.001 | | 0.007 | < 0.001 | 4.9 | 5.5 | 0.5 | 89.1 | | | |
| | DR(<i>k</i> =1) | JM-mis | 0.001 | 0.001 | 0.006 | 0.009 | -0.003 | 5.0 | 5.0 | 0.4 | 89.6 | | | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | | 0.001 | | 0.007 | -0.003 | 5.1 | 4.8 | 0.3 | 89.8 | | | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =1) | 0.001 | 0.001 | 0.006 | 0.007 | -0.002 | 5.7 | 4.7 | 0.4 | 89.2 | | | |
| | | CM-obs | 0.001 | 0.001 | 0.006 | 0.008 | 0.038 | 5.0 | 4.2 | 0.4 | 90.4 | | | |
| | | | | | | | | Indirect | Direct | Direct & | Not Direct & | | | |
| | | | $\beta_{g,1}=0$ | <i>γg</i> ,2= 0.7 | $\widehat{\sigma_{\beta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{1,2}}$ | muncet | | Indirect | Not Indirect | | | |
| CND4 | | | | | | | | 0 | 94.98 | 5.0 | 0.02 | | | |
| SNP4 (MAF= | HbA1c(<i>l</i> =1)/ | JM-cmp | 0.001 | -0.014 | 0.006 | 0.017 | -0.010 | 0 | 94.6 | 5.4 | 0 | | | |
| (MAI - 30%) | DN(<i>k</i> =2) | JM-mis | | -0.028 | | 0.019 | -0.010 | 0 | 94.6 | 5.4 | 0 | | | |
| 5070) | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | -0.076 | | 0.017 | -0.009 | 0 | 94.5 | 5.4 | 0.1 | | | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =2) | 0.001 | -0.281 | 0.006 | 0.015 | 0.007 | 0.3 | 88.1 | 5.8 | 5.8 | | | |
| | | CM-obs | 0.001 | -0.216 | 0.006 | 0.013 | 0.025 | 0 | 93.5 | 5.4 | 1.1 | | | |
| | | | $\beta_{g,2}=0$ | γ _{g,2} =0.7 | $\widehat{\sigma_{eta_{g,2}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{2,2}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | | | |
| | | | | | . 9, | 9, | , | 0 | 94.98 | 5.0 | 0.02 | | | |
| | SBP(<i>l</i> =2)/ | JM-cmp | | -0.014 | | 0.017 | -0.026 | 0 | 95.2 | 4.8 | 0 | | | |
| | DN(k=2) | JM-mis | 0.012 | -0.028 | 0.215 | 0.019 | -0.021 | 0 | 95.2 | 4.8 | 0 | | | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | -0.076 | | 0.017 | -0.020 | 0 | 95.1 | 4.8 | 0.1 | | | |
| | | JM-sep(<i>l</i> =2; <i>k</i> =2) | 0.012 | -0.088 | 0.215 | 0.016 | -0.019 | 0 | 95.1 | 4.8 | 0.1 | | | |
| | | CM-obs | 0.012 | -0.216 | 0.215 | 0.013 | 0.332 | 0.1 | 94.2 | 4.7 | 1.0 | | | |

¹Mean Bias in the SNP4 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

²Mean Bootstrap SE's, $\sigma_{\beta_{a,l}}$ and $\sigma_{\gamma_{a,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the *R*=1000 replicates.

³*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP4 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

<u>**Table 6.**</u> Classification frequencies for SNP5 association with each pair of QT/time-to-event traits based on the complete joint model and compared models at significance threshold $P^*=0.05$, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

| SNP | Trait pairs | Analysis Model | Mea | n Bias ¹ | | ootstrap S Correlation | | Classification frequencies ³ (%) Expected (above) vs Empirical Values | | | | |
|-----------|--|-------------------------------------|---------------------|-----------------------|------------------------------------|-----------------------------------|--|---|--------|----------------------|------------------------------|--|
| | | | $\beta_{g,1}=0$ | $\gamma_{g,1}=0$ | $\widehat{\sigma_{\!\beta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,1}}}$ | $\widehat{\rho_{1,1}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | - | | - <u>9</u> ,- | 3,- | | 4.75 | 4.75 | 0.25 | 90.25 | |
| | HbA1c(l=1)/ | JM-cmp | | < 0.001 | | 0.012 | 0.001 | 2.4 | 5.1 | 0.4 | 92.1 | |
| | DR(<i>k</i> =1) | JM-mis | -0.021 | 0.017 | 0.010 | 0.015 | < 0.001 | 2.4 | 4.2 | 0.4 | 93.0 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | | 0.013 | | 0.012 | < 0.001 | 2.4 | 4.4 | 0.4 | 92.8 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =1) | -0.019 | 0.013 | 0.010 | 0.012 | -0.003 | 2.6 | 4.4 | 0.2 | 92.8 | |
| | | CM-obs | -0.021 | 0.019 | 0.010 | 0.013 | 0.043 | 2.4 | 4.4 | 0.4 | 92.8 | |
| | | | | | $\widehat{\sigma_{\beta_{g,1}}}$ | | $\widehat{\rho_{\gamma_{g,2}}}$ $\widehat{\rho_{1,2}}$ | Indirect | Direct | Direct & | Not Direct & | |
| | HbA1c(<i>l</i> =1)/ DN(<i>k</i> =2) | | β _{g,1} =0 | γ _{g,2} =0.4 | | $\widehat{\sigma_{\gamma_{g,2}}}$ | | | | Indirect | Not Indirect | |
| | | | | | | | | 1.44 | 67.67 | 3.56 | 27.33 | |
| SNP5 | | JM-cmp | -0.021 | -0.020 | 0.010 | 0.025 | -0.016 | 1.1 | 64.7 | 1.7 | 32.5 | |
| (MAF=20%) | | JM-mis | | -0.009 | | 0.029 | -0.013 | 0.8 | 62.5 | 2.0 | 34.7 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | -0.036 | | 0.026 | -0.014 | 1.2 | 61.6 | 1.6 | 35.6 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =2) | -0.019 | 0.765 | 0.010 | 0.021 | -0.008 | 0 | 97.2 | 2.8 | 0 | |
| | | CM-obs | -0.021 | 0.505 | 0.010 | 0.022 | 0.017 | 0 | 97.2 | 2.8 | 0 | |
| | | | β _{g,2} =7 | γ _{g,2} =0.4 | $\widehat{\sigma_{eta_{g,2}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{2,2}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | 1 8,- | 18,- | P y,2 | r y,2 | 1 2,2 | 28.77 | 0 | 71.23 | 0 | |
| | SBP(<i>l</i> =2)/ | JM-cmp | | -0.020 | | 0.025 | -0.050 | 33.6 | 0 | 66.4 | 0 | |
| | DN(k=2) | JM-mis | 0.046 | -0.009 | 0.385 | 0.029 | -0.047 | 35.5 | 0 | 64.5 | 0 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | -0.036 | | 0.026 | -0.047 | 36.8 | 0 | 63.2 | 0 | |
| | | JM-sep(<i>l</i> =2; <i>k</i> =2) | 0.039 | -0.029 | 0.384 | 0.025 | -0.041 | 35.1 | 0 | 64.9 | 0 | |
| | | CM-obs | 0.046 | 0.505 | 0.385 | 0.022 | 0.280 | 0 | 0 | 100 | 0 | |

¹Mean Bias in the SNP5 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

²Mean Bootstrap SE's, $\sigma_{\beta_{a,l}}$ and $\sigma_{\gamma_{a,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the *R*=1000 replicates.

³*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP5 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect, calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

<u>**Table 7.**</u> Classification frequencies for SNP3 association with each pair of QT/time-to-event traits based on the complete joint model and compared models at significance threshold $P^*=0.05$, using R=1000 replicates of N=667 DCCT subjects, with SNPs simulated under the *alternative* genetic scenario from Fig. 3

| SNP | Trait pairs | Analysis Model | Mean | Bias ¹ | Mean | Bootstrap SI Correlation ² | | Classification frequencies ³ (%) Expected (above) vs Empirical Values | | | | |
|-------------------|--|-------------------------------------|-----------------|---------------------|----------------------------------|--|------------------------|---|--------|----------------------|------------------------------|--|
| | | | $\beta_{g,1}=0$ | γ _{g,1} =0 | $\widehat{\sigma_{eta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,1}}}$ | $\widehat{\rho_{1,1}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | | | 0, | <u>,</u> | | 4.75 | 4.75 | 0.25 | 90.25 | |
| | HbA1c(<i>l</i> =1)/ | JM-cmp | | 0.001 | | 0.009 | -0.001 | 4.3 | 4.5 | 0.2 | 91.0 | |
| | DR(<i>k</i> =1) | JM-mis | -0.012 | 0.299 | 0.006 | 0.009 | -0.004 | 0.7 | 86.1 | 3.8 | 9.4 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =1) | | 0.274 | | 0.007 | -0.004 | 0.6 | 85.8 | 3.9 | 9.7 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =1) | -0.014 | 0.274 | 0.006 | 0.007 | -0.003 | 0.5 | 85.4 | 4.3 | 9.8 | |
| | | CM-obs | -0.012 | 0.280 | 0.006 | 0.008 | 0.035 | 0.7 | 85.5 | 3.8 | 10.0 | |
| | | | | | | | | Indirect | Direct | Direct & | Not Direct & | |
| | HbA1c(<i>l</i> =1)/ DN(<i>k</i> =2) | | $\beta_{g,1}=0$ | γ _{g,2} =0 | $\widehat{\sigma_{\beta_{g,1}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{1,2}}$ | | | Indirect | Not Indirect | |
| | | | | | | | | 4.75 | 4.75 | 0.25 | 90.25 | |
| SNP3 ⁴ | | JM-cmp | -0.012 | 0.004 | .305 0.006 | 0.021 | -0.012 | 4.5 | 3.8 | 0 | 91.7 | |
| (MAF=40%) | | JM-mis | | 0.305 | | 0.021 | -0.016 | 1.7 | 55.6 | 2.8 | 39.9 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | 0.291 | | 0.019 | -0.016 | 1.6 | 54.8 | 2.9 | 40.7 | |
| | | JM-sep(<i>l</i> =1; <i>k</i> =2) | -0.014 | 0.197 | 0.006 | 0.017 | 0.005 | 3.2 | 31.4 | 1.6 | 63.8 | |
| | | CM-obs | -0.012 | 0.228 | 0.006 | 0.015 | 0.019 | 2.3 | 46.0 | 2.2 | 49.5 | |
| | | | $\beta_{g,2}=0$ | γ _{g,2} =0 | $\widehat{\sigma_{eta_{g,2}}}$ | $\widehat{\sigma_{\gamma_{g,2}}}$ | $\widehat{\rho_{2,2}}$ | Indirect | Direct | Direct & Indirect | Not Direct & Not Indirect | |
| | | | | | . 9,- | 3,- | , | 4.75 | 4.75 | 0.25 | 90.25 | |
| | SBP(<i>l</i> =2)/ | JM-cmp | | 0.004 | | 0.021 | -0.017 | 4.4 | 3.6 | 0.2 | 91.8 | |
| | DN(k=2) | JM-mis | 0.157 | 0.305 | 0.211 | 0.021 | -0.017 | 1.8 | 55.6 | 2.8 | 39.8 | |
| | | JM-sep(<i>l</i> =1,2; <i>k</i> =2) | | 0.291 | | 0.019 | -0.015 | 1.8 | 54.9 | 2.8 | 40.5 | |
| | | JM-sep(<i>l</i> =2; <i>k</i> =2) | 0.156 | 0.282 | 0.212 | 0.018 | -0.009 | 1.8 | 53.8 | 2.6 | 41.8 | |
| | | CM-obs | 0.157 | 0.228 | 0.211 | 0.015 | 0.316 | 1.4 | 45.0 | 3.2 | 50.4 | |

¹Mean Bias in the SNP3 effects, $\widehat{\beta_{g,l}}$ and $\widehat{\gamma_{g,k}}$, estimated by each of the analysis models.

²Mean Bootstrap SE's, $\sigma_{\beta_{a,l}}$ and $\sigma_{\gamma_{a,k}}$, for respectively $\beta_{g,l}$ and $\gamma_{g,k}$, and their correlation $\rho_{l,k}$ over the *R*=1000 replicates.

³*Expected* and *empirical* frequencies (shown as percentage, %) to classify SNP3 association as Direct, Indirect, Direct & Indirect, or Not Direct & Not Indirect calculated as described in the footnote of Table 3. Empirical classification frequencies at significance levels $P^* \leq 10^{-5}$, and their 95% confidence intervals are presented in File S2 (section 11).

⁴All the models, except JM-cmp, do not account for the indirect genetic pathways via the intermediate longitudinal risk factor U. This translates into a large bias in the direct genetic effects $\gamma_{a,k}$ on both time-to-T1DC traits, and increased misclassification rates for SNP3 as a direct association.